169 results on '"Haymaker C"'
Search Results
2. HER2-low expression in patients with advanced or metastatic solid tumors
- Author
-
Uzunparmak, B., Haymaker, C., Raso, G., Masciari, S., Wang, L., Lin, H., Gorur, A., Kirby, B., Cimo, A.-M., Kennon, A., Ding, Q., Urschel, G., Yuan, Y., Feng, G., Rizvi, Y., Hussain, A., Zhu, C., Kim, P., Abbadessa, G., Subbiah, V., Yap, T.A., Rodon, J., Piha-Paul, S.A., Meric-Bernstam, F., and Dumbrava, E.E.
- Published
- 2023
- Full Text
- View/download PDF
3. 94P Diversity of liposarcoma expanded tumor-infiltrating lymphocytes metabolism linked to LAG3 expression
- Author
-
Haymaker, C., primary, Ramirez, J. Oliva, additional, Lee, Y., additional, Tomczak, K., additional, Truong, D.D., additional, Zhou, X., additional, Ravi, V., additional, Conley, A.P., additional, Ingram, D., additional, Livingston, J.A., additional, Ludwing, J., additional, and Somaiah, N., additional
- Published
- 2024
- Full Text
- View/download PDF
4. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer
- Author
-
Kudo, Y., Haymaker, C., Zhang, J., Reuben, A., Duose, D.Y., Fujimoto, J., Roy-Chowdhuri, S., Solis Soto, L.M., Dejima, H., Parra, E.R., Mino, B., Abraham, R., Ikeda, N., Vaporcyan, A., Gibbons, D., Lang, F.F., Luthra, R., Lee, J.J., Moran, C., Huse, J.T., Kadara, H., and Wistuba, I.I.
- Published
- 2019
- Full Text
- View/download PDF
5. Peripheral T-Cell Priming and Micrometastatic Disease Control with Metastasis-Directed Therapy: Multidimensional Immunogenomic Profiling of Oligometastatic Prostate Cancer in the EXTEND Trial
- Author
-
Sherry, A.D., primary, Haymaker, C., additional, Bathala, T., additional, Lu, X., additional, Medina-Rosales, M., additional, Marmonti, E., additional, Pradeep, H., additional, Liu, S., additional, Fellman, B., additional, Mok, H., additional, Choi, S., additional, Chun, S.G., additional, Aparicio, A., additional, Kovitz, C., additional, Zurita-Saavedra, A., additional, Gomez, D.R., additional, Reuben, A., additional, Wistuba, I., additional, Corn, P.G., additional, and Tang, C., additional
- Published
- 2023
- Full Text
- View/download PDF
6. 103P Analysis of resected liposarcoma tumors identifies CD73 as a potential therapeutic target
- Author
-
Oliva Ramirez, J., primary, Lee, Y., additional, Rodriguez, R., additional, Tomczak, K., additional, Zhou, X., additional, Ravi, V., additional, Conley, A.P., additional, Ingram, D., additional, Livingston, J., additional, Ludwing, J., additional, Somaiah, N., additional, and Haymaker, C., additional
- Published
- 2023
- Full Text
- View/download PDF
7. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer (EXTEND): A Multicenter, Randomized Phase II Trial
- Author
-
Tang, C., primary, Sherry, A.D., additional, Haymaker, C., additional, Bathala, T., additional, Liu, S., additional, Fellman, B., additional, Aparicio, A., additional, Zurita-Saavedra, A., additional, Chun, S.., additional, Reddy, J., additional, Efstathiou, E., additional, Wang, J., additional, Pilie, P., additional, Reuben, A., additional, Kovitz, C., additional, Kumar, R., additional, Chapin, B., additional, Gomez, D.R., additional, Wistuba, I., additional, and Corn, P.G., additional
- Published
- 2022
- Full Text
- View/download PDF
8. 1674P NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment: Biomarker data from the NIT-110 study
- Author
-
Naing, A., primary, Ferrando-Martinez, S., additional, Wolfarth, A., additional, Xu, M., additional, Goon, J.B., additional, Ware, M.B., additional, Haymaker, C., additional, Raso, M.G., additional, Chaney, M., additional, Ezeanya, U.I., additional, Dhar, S., additional, Lee, H., additional, Lee, T., additional, Adebanjo, T., additional, Fan, J., additional, Yang, S.H., additional, Lee, B.H., additional, and Kim, R., additional
- Published
- 2022
- Full Text
- View/download PDF
9. P-48 Phase 2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab: Cohort of subjects with checkpoint inhibitor-naïve advanced pancreatic cancer
- Author
-
Naing, A., primary, Mamdani, H., additional, Barve, M., additional, Johnson, M., additional, Wolff, R., additional, Kim, D., additional, Yang, S., additional, Lee, B., additional, Adebanjo, T., additional, Georgevitch, R., additional, Ferrando-Martinez, S., additional, Haymaker, C., additional, Chaney, M., additional, Fan, J., additional, Kim, R., additional, and Pant, S., additional
- Published
- 2022
- Full Text
- View/download PDF
10. 123P Clinical and environment factors impacting malignant pleural mesothelioma prognosis
- Author
-
Deboever, N.O.T., primary, McGrail, D., additional, Zhou, N., additional, Altan, M., additional, Olivia, J., additional, Parra, E., additional, Zhang, J., additional, Lee, P., additional, Rajaram, R., additional, Hofstetter, W., additional, Vaporciyan, A., additional, Mehran, R., additional, Rice, D., additional, Tomczak, K., additional, Weissferdt, A., additional, Tsao, A., additional, Haymaker, C., additional, and Sepesi, B., additional
- Published
- 2022
- Full Text
- View/download PDF
11. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer
- Author
-
Federico, L., primary, McGrail, D.J., additional, Bentebibel, S.-E., additional, Haymaker, C., additional, Ravelli, A., additional, Forget, M.-A., additional, Karpinets, T., additional, Jiang, P., additional, Reuben, A., additional, Negrao, M.V., additional, Li, J., additional, Khairullah, R., additional, Zhang, J., additional, Weissferdt, A., additional, Vaporciyan, A.A., additional, Antonoff, M.B., additional, Walsh, G., additional, Lin, S.-Y., additional, Futreal, A., additional, Wistuba, I., additional, Roth, J., additional, Byers, L.A., additional, Gaudreau, P.-O., additional, Uraoka, N., additional, Cruz, A.F., additional, Dejima, H., additional, Lazcano, R.N., additional, Solis, L.M., additional, Parra, E.R., additional, Lee, J.J., additional, Swisher, S., additional, Cascone, T., additional, Heymach, J.V., additional, Sepesi, B., additional, Gibbons, D.L., additional, and Bernatchez, C., additional
- Published
- 2022
- Full Text
- View/download PDF
12. 7P Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC
- Author
-
Rocha, P., primary, Zhang, J., additional, Laza-Briviesca, R., additional, Cruz-Bermúdez, A., additional, Yoshimura, K., additional, Behrens, C., additional, Pataer, A., additional, Parra, E.R., additional, Haymaker, C., additional, Fujimoto, J., additional, Swisher, S.G., additional, Heymach, J.V., additional, Gibbons, D.L., additional, Lee, J.J., additional, Sepesi, B., additional, Cascone, T., additional, Solis, L.M., additional, Provencio, M., additional, Kadara, H., additional, and Wistuba, I.I., additional
- Published
- 2021
- Full Text
- View/download PDF
13. 1024P Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab
- Author
-
Parra, E.R., primary, Adriani, M., additional, Freitas Pinto Lima, C., additional, Li, J., additional, Haymaker, C., additional, Parikh, R., additional, Bernicker, E., additional, Davar, D., additional, Chaudhry, A., additional, Stevenson, A., additional, Badham, C., additional, Fyvie, G., additional, Chisamore, M., additional, and Pant, S., additional
- Published
- 2021
- Full Text
- View/download PDF
14. FP05.03 Association between Baseline Tumor Thickness and Response to Neoadjuvant Chemotherapy in Malignant Pleural Mesothelioma
- Author
-
Zhou, N., primary, Rice, D., additional, Mehran, R., additional, Feldman, H., additional, Tomczak, K., additional, Hofstetter, W., additional, Vaporciyan, A., additional, Correa, A., additional, Zhang, J., additional, Haymaker, C., additional, Tsao, A., additional, and Sepesi, B., additional
- Published
- 2021
- Full Text
- View/download PDF
15. 1083MO Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
- Author
-
Haymaker, C., primary, Andtbacka, R.H.I., additional, Johnson, D.B., additional, Shaheen, M.F., additional, Rahimian, S., additional, Chunduru, S., additional, Gabrail, N., additional, Doolittle, G., additional, Puzanov, I., additional, Markowitz, J., additional, Bernatchez, C., additional, and Diab, A., additional
- Published
- 2020
- Full Text
- View/download PDF
16. 1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours
- Author
-
Babiker, H., primary, Borazanci, E., additional, Subbiah, V., additional, Algazi, A.P., additional, Schachter, J., additional, Lotem, M., additional, Hendler, D., additional, Rahimian, S., additional, Minderman, H., additional, Haymaker, C., additional, Bernatchez, C., additional, Murthy, R., additional, Hultsch, R., additional, Caplan, N., additional, Woodhead, G.J., additional, Hennemeyer, C.T., additional, Chunduru, S., additional, Anderson, P., additional, Diab, A., additional, and Puzanov, I., additional
- Published
- 2020
- Full Text
- View/download PDF
17. P1.04-11 Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data
- Author
-
Gaudreau, P., primary, Ajami, N., additional, Sepesi, B., additional, Karpinets, T., additional, Reuben, A., additional, Wong, M., additional, Parra, E., additional, Federico, L., additional, Gopalakrishnan, V., additional, Mitchell, K., additional, Negrao, M., additional, Spencer, C., additional, Vaporciyan, A., additional, Weissferdt, A., additional, Haymaker, C., additional, Tran, H., additional, Bernatchez, C., additional, Landry, L., additional, Roarty, E., additional, Cascone, T., additional, Heymach, J., additional, Zhang, J., additional, Wistuba, I., additional, Wargo, J., additional, and Gibbons, D., additional
- Published
- 2019
- Full Text
- View/download PDF
18. P2.04-19 Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC
- Author
-
Gaudreau, P., primary, Negrao, M., additional, Mitchell, K., additional, Corsini, E., additional, Karpinets, T., additional, Wang, Q., additional, Diao, L., additional, Wang, J., additional, Federico, L., additional, Parra, E., additional, Li, J., additional, Behrens, C., additional, Correa, A., additional, Gomez, D., additional, Vaporciyan, A., additional, Weissferdt, A., additional, Tran, H., additional, Roarty, E., additional, Wistuba, I., additional, Reuben, A., additional, Haymaker, C., additional, Bernatchez, C., additional, Cascone, T., additional, Heymach, J., additional, Sepesi, B., additional, Zhang, J., additional, and Gibbons, D., additional
- Published
- 2019
- Full Text
- View/download PDF
19. Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101
- Author
-
Babiker, H., primary, Borazanci, E., additional, Subbiah, V., additional, Maguire, O., additional, Rahimian, S., additional, Minderman, H., additional, Haymaker, C., additional, Bernatchez, C., additional, Bindra, G., additional, Iverson, I., additional, Chunduru, S., additional, Anderson, P., additional, Puzanov, I., additional, and Diab, A., additional
- Published
- 2019
- Full Text
- View/download PDF
20. P1.04-07 Immune Suppressive Microenvironment and Highly Clonal Concordance of TCR Repertoire in Brain Metastases from Non-Small Cell Lung Cancer
- Author
-
Kudo, Y., primary, Haymaker, C., additional, Zhang, J., additional, Reuben, A., additional, Duose, D., additional, Fujimoto, J., additional, Roy-Chowdhuri, S., additional, Solis, L., additional, Dejima, H., additional, Cuentas, E. Parra, additional, Mino, B., additional, Ikeda, N., additional, Luthra, R., additional, Gibbons, D., additional, Lang, F., additional, Lee, J.J., additional, Huse, J., additional, Kadara, H., additional, and Wistuba, I., additional
- Published
- 2019
- Full Text
- View/download PDF
21. P1.03-12 PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers
- Author
-
Sepesi, B., primary, Federico, L., additional, Mitchell, K., additional, Parra, E., additional, Francisco Cruz, A., additional, Ravelli, A., additional, Haymaker, C., additional, Karpinets, T., additional, Cascone, T., additional, Weissferdt, A., additional, Antonoff, M.B., additional, Walsh, G., additional, Bernatchez, C., additional, Roth, J., additional, Zhang, J., additional, Roarty, E., additional, Landry, L.C.A.D.L., additional, Vaporciyan, A., additional, Swisher, S., additional, Heymach, J., additional, Wistuba, I., additional, and Gibbons, D., additional
- Published
- 2018
- Full Text
- View/download PDF
22. Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study
- Author
-
Diab, A., primary, Haymaker, C., additional, Bernatchez, C., additional, Andtbacka, R.H.I., additional, Shaheen, M., additional, Johnson, D., additional, Markowitz, J., additional, Puzanov, I., additional, Murthy, R., additional, Johnson, D.H., additional, James, M., additional, Chunduru, S., additional, Geib, J., additional, Swann, S., additional, Rahimian, S., additional, and Hwu, P., additional
- Published
- 2018
- Full Text
- View/download PDF
23. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
- Author
-
Cascone, T., primary, William, W.N., additional, Weissferdt, A., additional, Leung, C.H., additional, Federico, L., additional, Haymaker, C., additional, Bernatchez, C., additional, Fossella, F.V., additional, Mott, F.E., additional, Papadimitrakopoulou, V.A., additional, Byers, L., additional, Lam, V.K., additional, Godoy, M.C., additional, Carter, B., additional, Lee, J.J., additional, Vaporciyan, A., additional, Gibbons, D.L., additional, Swisher, S.G., additional, Heymach, J.V., additional, and Sepesi, B., additional
- Published
- 2018
- Full Text
- View/download PDF
24. MA06.02 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON
- Author
-
Negrao, M., primary, Reuben, A., additional, Chen, R., additional, Sepesi, B., additional, Karpinets, T., additional, Parra, E., additional, Federico, L., additional, Vence, L., additional, Weissferdt, A., additional, Tran, H., additional, Vaporciyan, A., additional, Haymaker, C., additional, Forget, M., additional, Vasquez, M., additional, Prado, E., additional, Chow, C., additional, Zhang, J., additional, Fujimoto, J., additional, Roth, J.A. Jack A., additional, Meraz, I.M., additional, Roarty, E., additional, Landry, L.L., additional, Wagner, H., additional, Bogatenkova, E., additional, Bernatchez, C., additional, Futreal, P.A., additional, Wistuba, I., additional, Swisher, S., additional, Heymach, J., additional, and Gibbons, D., additional
- Published
- 2018
- Full Text
- View/download PDF
25. OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues
- Author
-
Reuben, A., primary, Gittelman, R., additional, Zhang, J., additional, Chen, R., additional, Quek, K., additional, Vence, L., additional, Fernandez-Cubelo, I., additional, Behrens, C., additional, Gao, J., additional, Yusko, E., additional, Emerson, R., additional, Benzeno, S., additional, Vignali, M., additional, Tipton, C., additional, Jalali, A., additional, Lee, W., additional, Wu, C., additional, Li, J., additional, Wu, X., additional, Ye, Y., additional, Eterovic, A., additional, Little, L., additional, Gumbs, C., additional, Bernatchez, C., additional, Haymaker, C., additional, Forget, M., additional, Federico, L., additional, Cascone, T., additional, Robins, H., additional, Roarty, E., additional, Rodriguez, J., additional, Parra, E., additional, Wargo, J., additional, Allison, J., additional, Sharma, P., additional, Lee, J., additional, Sepesi, B., additional, Swisher, S., additional, Gibbons, D., additional, Heymach, J., additional, Futreal, A., additional, and Wistuba, I., additional
- Published
- 2017
- Full Text
- View/download PDF
26. P2.07-062 PIVOT-02: Phase 1/2 Study of NKTR-214 and Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies
- Author
-
Papadimitrakopoulou, V., primary, Tannir, N., additional, Bernatchez, C., additional, Haymaker, C., additional, Bentebibel, S., additional, Curti, B., additional, Wong, M., additional, Gergel, I., additional, Tagliaferri, M., additional, Zalevsky, J., additional, Hoch, U., additional, Aung, S., additional, Imperiale, M., additional, Cho, D., additional, Tykodi, S., additional, Puzanov, I., additional, Kluger, H., additional, Hurwitz, M., additional, Hwu, P., additional, Sznol, M., additional, and Diab, A., additional
- Published
- 2017
- Full Text
- View/download PDF
27. A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma
- Author
-
Diab, A., primary, Haymaker, C., additional, Uemura, M., additional, Murthy, R., additional, James, M., additional, Geib, J., additional, Cornfeld, M., additional, Swann, S., additional, Yee, C., additional, Wargo, J., additional, Amaria, R., additional, Patel, S., additional, Tawbi, H., additional, Glitza, I., additional, Woodman, S., additional, Hwu, W.-J., additional, Davies, M.A., additional, Overwijk, W., additional, Bernatchez, C., additional, and Hwu, P., additional
- Published
- 2017
- Full Text
- View/download PDF
28. Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer
- Author
-
Glisson, B., primary, Massarelli, E., additional, William, W.N., additional, Johnson, F.M., additional, Kies, M.S., additional, Ferrarotto, R., additional, Guo, M., additional, Peng, S.A., additional, Lee, J.J., additional, Tran, H., additional, Kim, Y.U., additional, Haymaker, C., additional, Bernatchez, C., additional, Curran, M., additional, Sanchez Espiridion, B., additional, Rodriguez Canales, J., additional, Wistuba, I.I., additional, van der Burg, S., additional, Wang, J., additional, and Melief, C., additional
- Published
- 2017
- Full Text
- View/download PDF
29. PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
- Author
-
Diab, A., primary, Hurwitz, M.E., additional, Tannir, N., additional, Bernatchez, C., additional, Haymaker, C., additional, Bentebibel, S.E., additional, Curti, B.D., additional, Wong, M.K.K., additional, Gergel, I., additional, Tagliaferri, M., additional, Zalevsky, J., additional, Hoch, U., additional, Aung, S., additional, Imperiale, M., additional, Cho, D., additional, Tykodi, S.S., additional, Puzanov, I., additional, Kluger, H., additional, Hwu, P., additional, and Sznol, M., additional
- Published
- 2017
- Full Text
- View/download PDF
30. Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
- Author
-
Bailey, P, Chang, DK, Forget, MA, Lucas, FAS, Alvarez, HA, Haymaker, C, Chattopadhyay, C, Kim, SH, Ekmekcioglu, S, Grimm, EA, Biankin, AV, Hwu, P, Maitra, A, Roszik, J, Bailey, P, Chang, DK, Forget, MA, Lucas, FAS, Alvarez, HA, Haymaker, C, Chattopadhyay, C, Kim, SH, Ekmekcioglu, S, Grimm, EA, Biankin, AV, Hwu, P, Maitra, A, and Roszik, J
- Abstract
© 2016 The Author(s). Immunotherapy approaches for pancreatic ductal adenocarcinoma (PDAC) have met with limited success. It has been postulated that a low mutation load may lead to a paucity of T cells within the tumor microenvironment (TME). However, it is also possible that while neoantigens are present, an effective immune response cannot be generated due to an immune suppressive TME. To discern whether targetable neoantigens exist in PDAC, we performed a comprehensive study using genomic profiles of 221 PDAC cases extracted from public databases. Our findings reveal that: (a) nearly all PDAC samples harbor potentially targetable neoantigens; (b) T cells are present but generally show a reduced activation signature; and (c) markers of efficient antigen presentation are associated with a reduced signature of markers characterizing cytotoxic T cells. These findings suggest that despite the presence of tumor specific neoepitopes, T cell activation is actively suppressed in PDAC. Further, we identify iNOS as a potential mediator of immune suppression that might be actionable using pharmacological avenues.
- Published
- 2016
31. 1195P - Safety, efficacy, and immune effects of intratumoral tilsotolimod in patients with refractory solid tumours: Updated results from ILLUMINATE-101
- Author
-
Babiker, H., Borazanci, E., Subbiah, V., Maguire, O., Rahimian, S., Minderman, H., Haymaker, C., Bernatchez, C., Bindra, G., Iverson, I., Chunduru, S., Anderson, P., Puzanov, I., and Diab, A.
- Published
- 2019
- Full Text
- View/download PDF
32. LBA49 - Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
- Author
-
Cascone, T., William, W.N., Weissferdt, A., Leung, C.H., Federico, L., Haymaker, C., Bernatchez, C., Fossella, F.V., Mott, F.E., Papadimitrakopoulou, V.A., Byers, L., Lam, V.K., Godoy, M.C., Carter, B., Lee, J.J., Vaporciyan, A., Gibbons, D.L., Swisher, S.G., Heymach, J.V., and Sepesi, B.
- Published
- 2018
- Full Text
- View/download PDF
33. 1245PD - Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study
- Author
-
Diab, A., Haymaker, C., Bernatchez, C., Andtbacka, R.H.I., Shaheen, M., Johnson, D., Markowitz, J., Puzanov, I., Murthy, R., Johnson, D.H., James, M., Chunduru, S., Geib, J., Swann, S., Rahimian, S., and Hwu, P.
- Published
- 2018
- Full Text
- View/download PDF
34. 1212TiP - PIVOT-02: A phase 1/2, open-label, multicenter, dose escalation and dose expansion study of NKTR-214 and nivolumab in patients with select, locally advanced or metastatic solid tumor malignancies
- Author
-
Diab, A., Hurwitz, M.E., Tannir, N., Bernatchez, C., Haymaker, C., Bentebibel, S.E., Curti, B.D., Wong, M.K.K., Gergel, I., Tagliaferri, M., Zalevsky, J., Hoch, U., Aung, S., Imperiale, M., Cho, D., Tykodi, S.S., Puzanov, I., Kluger, H., Hwu, P., and Sznol, M.
- Published
- 2017
- Full Text
- View/download PDF
35. 1187P - A Phase 1/2 trial of intratumoral (i.t.) IMO-2125 (IMO) in combination with checkpoint inhibitors (CPI) in PD-(L)1-refractory melanoma
- Author
-
Diab, A., Haymaker, C., Uemura, M., Murthy, R., James, M., Geib, J., Cornfeld, M., Swann, S., Yee, C., Wargo, J., Amaria, R., Patel, S., Tawbi, H., Glitza, I., Woodman, S., Hwu, W.-J., Davies, M.A., Overwijk, W., Bernatchez, C., and Hwu, P.
- Published
- 2017
- Full Text
- View/download PDF
36. 1136O - Nivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer
- Author
-
Glisson, B., Massarelli, E., William, W.N., Johnson, F.M., Kies, M.S., Ferrarotto, R., Guo, M., Peng, S.A., Lee, J.J., Tran, H., Kim, Y.U., Haymaker, C., Bernatchez, C., Curran, M., Sanchez Espiridion, B., Rodriguez Canales, J., Wistuba, I.I., van der Burg, S., Wang, J., and Melief, C.
- Published
- 2017
- Full Text
- View/download PDF
37. Human genome meeting 2016
- Author
-
Srivastava, A., Wang, Y., Huang, R., Skinner, C., Thompson, T., Pollard, L., Wood, T., Luo, F., Stevenson, R., Polimanti, R., Gelernter, J., Lin, X., Lim, I., Wu, Y., Teh, A., Chen, L., Aris, I., Soh, S., Tint, M., MacIsaac, J., Yap, F., Kwek, K., Saw, S., Kobor, M., Meaney, M., Godfrey, K., Chong, Y., Holbrook, J., Lee, Y., Gluckman, P., Karnani, N., Kapoor, A., Lee, D., Chakravarti, A., Maercker, C., Graf, F., Boutros, M., Stamoulis, G., Santoni, F., Makrythanasis, P., Letourneau, A., Guipponi, M., Panousis, N., Garieri, M., Ribaux, P., Falconnet, E., Borel, C., Antonarakis, S., Kumar, S., Curran, J., Blangero, J., Chatterjee, S., Kapoor, A., Akiyama, J., Auer, D., Berrios, C., Pennacchio, L., Chakravarti, A., Donti, T., Cappuccio, G., Miller, M., Atwal, P., Kennedy, A., Cardon, A., Bacino, C., Emrick, L., Hertecant, J., Baumer, F., Porter, B., Bainbridge, M., Bonnen, P., Graham, B., Sutton, R., Sun, Q., Elsea, S., Hu, Z., Wang, P., Zhu, Y., Zhao, J., Xiong, M., Bennett, David, Hidalgo-Miranda, A., Romero-Cordoba, S., Rodriguez-Cuevas, S., Rebollar-Vega, R., Tagliabue, E., Iorio, M., D’Ippolito, E., Baroni, S., Kaczkowski, B., Tanaka, Y., Kawaji, H., Sandelin, A., Andersson, R., Itoh, M., Lassmann, T., Hayashizaki, Y., Carninci, P., Forrest, A., Semple, C., Rosenthal, E., Shirts, B., Amendola, L., Gallego, C., Horike-Pyne, M., Burt, A., Robertson, P., Beyers, P., Nefcy, C., Veenstra, D., Hisama, F., Bennett, R., Dorschner, M., Nickerson, D., Smith, J., Patterson, K., Crosslin, D., Nassir, R., Zubair, N., Harrison, T., Peters, U., Jarvik, G., Menghi, F., Inaki, K., Woo, X., Kumar, P., Grzeda, K., Malhotra, A., Kim, H., Ucar, D., Shreckengast, P., Karuturi, K., Keck, J., Chuang, J., Liu, E., Ji, B., Tyler, A., Ananda, G., Carter, G., Nikbakht, H., Montagne, M., Zeinieh, M., Harutyunyan, A., Mcconechy, M., Jabado, N., Lavigne, P., Majewski, J., Goldstein, J., Overman, M., Varadhachary, G., Shroff, R., Wolff, R., Javle, M., Futreal, A., Fogelman, D., Bravo, L., Fajardo, W., Gomez, H., Castaneda, C., Rolfo, C., Pinto, J., Akdemir, K., Chin, L., Futreal, A., Patterson, S., Statz, C., Mockus, S., Nikolaev, S., Bonilla, X., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V., Sharpe, H., McKee, T., Letourneau, A., Ribaux, P., Popadin, K., Basset-Seguin, N., Chaabene, R., Santoni, F., Andrianova, M., Guipponi, M., Garieri, M., Verdan, C., Grosdemange, K., Sumara, O., Eilers, M., Aifantis, I., Michielin, O., de Sauvage, F., Antonarakis, S., Likhitrattanapisal, S., Lincoln, S., Kurian, A., Desmond, A., Yang, S., Kobayashi, Y., Ford, J., Ellisen, L., Peters, T., Alvarez, K., Hollingsworth, E., Lopez-Terrada, D., Hastie, A., Dzakula, Z., Pang, A., Lam, E., Anantharaman, T., Saghbini, M., Cao, H., Gonzaga-Jauregui, C., Ma, L., King, A., Rosenzweig, E., Krishnan, U., Reid, J., Overton, J., Dewey, F., Chung, W., Small, K., DeLuca, A., Cremers, F., Lewis, R., Puech, V., Bakall, B., Silva-Garcia, R., Rohrschneider, K., Leys, M., Shaya, F., Stone, E., Sobreira, N., Schiettecatte, F., Ling, H., Pugh, E., Witmer, D., Hetrick, K., Zhang, P., Doheny, K., Valle, D., Hamosh, A., Jhangiani, S., Akdemir, Z., Bainbridge, M., Charng, W., Wiszniewski, W., Gambin, T., Karaca, E., Bayram, Y., Eldomery, M., Posey, J., Doddapaneni, H., Hu, J., Sutton, V., Muzny, D., Boerwinkle, E., Valle, D., Lupski, J., Gibbs, R., Shekar, S., Salerno, W., English, A., Mangubat, A., Bruestle, J., Thorogood, A., Knoppers, B., Takahashi, H., Nitta, K., Kozhuharova, A., Suzuki, A., Sharma, H., Cotella, D., Santoro, C., Zucchelli, S., Gustincich, S., Carninci, P., Mulvihill, J., Baynam, G., Gahl, W., Groft, S., Kosaki, K., Lasko, P., Melegh, B., Taruscio, D., Ghosh, R., Plon, S., Scherer, S., Qin, X., Sanghvi, R., Walker, K., Chiang, T., Muzny, D., Wang, L., Black, J., Boerwinkle, E., Weinshilboum, R., Gibbs, R., Karpinets, T., Calderone, T., Wani, K., Yu, X., Creasy, C., Haymaker, C., Forget, M., Nanda, V., Roszik, J., Wargo, J., Haydu, L., Song, X., Lazar, A., Gershenwald, J., Davies, M., Bernatchez, C., Zhang, J., Futreal, A., Woodman, S., Chesler, E., Reynolds, T., Bubier, J., Phillips, C., Langston, M., Baker, E., Xiong, M., Ma, L., Lin, N., Amos, C., Lin, N., Wang, P., Zhu, Y., Zhao, J., Calhoun, V., Xiong, M., Dobretsberger, O., Egger, M., Leimgruber, F., Sadedin, S., Oshlack, A., Antonio, V., Ono, N., Ahmed, Z., Bolisetty, M., Zeeshan, S., Anguiano, E., Ucar, D., Sarkar, A., Nandineni, M., Zeng, C., Shao, J., Cao, H., Hastie, A., Pang, A., Lam, E., Liang, T., Pham, K., Saghbini, M., Dzakula, Z., Chee-Wei, Y., Dongsheng, L., Lai-Ping, W., Lian, D., Hee, R., Yunus, Y., Aghakhanian, F., Mokhtar, S., Lok-Yung, C., Bhak, J., Phipps, M., Shuhua, X., Yik-Ying, T., Kumar, V., Boon-Peng, H., Campbell, I., Young, M., James, P., Rain, M., Mohammad, G., Kukreti, R., Pasha, Q., Akilzhanova, A., Guelly, C., Abilova, Z., Rakhimova, S., Akhmetova, A., Kairov, U., Trajanoski, S., Zhumadilov, Z., Bekbossynova, M., Schumacher, C., Sandhu, S., Harkins, T., Makarov, V., Doddapaneni, H., Glenn, R., Momin, Z., Dilrukshi, B., Chao, H., Meng, Q., Gudenkauf, B., Kshitij, R., Jayaseelan, J., Nessner, C., Lee, S., Blankenberg, K., Lewis, L., Hu, J., Han, Y., Dinh, H., Jireh, S., Walker, K., Boerwinkle, E., Muzny, D., Gibbs, R., Hu, J., Walker, K., Buhay, C., Liu, X., Wang, Q., Sanghvi, R., Doddapaneni, H., Ding, Y., Veeraraghavan, N., Yang, Y., Boerwinkle, E., Beaudet, A., Eng, C., Muzny, D., Gibbs, R., Worley, K., Liu, Y., Hughes, D., Murali, S., Harris, R., English, A., Qin, X., Hampton, O., Larsen, P., Beck, C., Han, Y., Wang, M., Doddapaneni, H., Kovar, C., Salerno, W., Yoder, A., Richards, S., Rogers, J., Lupski, J., Muzny, D., Gibbs, R., Meng, Q., Bainbridge, M., Wang, M., Doddapaneni, H., Han, Y., Muzny, D., Gibbs, R., Harris, R., Raveenedran, M., Xue, C., Dahdouli, M., Cox, L., Fan, G., Ferguson, B., Hovarth, J., Johnson, Z., Kanthaswamy, S., Kubisch, M., Platt, M., Smith, D., Vallender, E., Wiseman, R., Liu, X., Below, J., Muzny, D., Gibbs, R., Yu, F., Rogers, J., Lin, J., Zhang, Y., Ouyang, Z., Moore, A., Wang, Z., Hofmann, J., Purdue, M., Stolzenberg-Solomon, R., Weinstein, S., Albanes, D., Liu, C., Cheng, W., Lin, T., Lan, Q., Rothman, N., Berndt, S., Chen, E., Bahrami, H., Khoshzaban, A., Keshal, S., Bahrami, H., Khoshzaban, A., Keshal, S., Alharbi, K., Zhalbinova, M., Akilzhanova, A., Rakhimova, S., Bekbosynova, M., Myrzakhmetova, S., Matar, M., Mili, N., Molinari, R., Ma, Y., Guerrier, S., Elhawary, N., Tayeb, M., Bogari, N., Qotb, N., McClymont, S., Hook, P., Goff, L., McCallion, A., Kong, Y., Charette, J., Hicks, W., Naggert, J., Zhao, L., Nishina, P., Edrees, B., Athar, M., Al-Allaf, F., Taher, M., Khan, W., Bouazzaoui, A., Harbi, N., Safar, R., Al-Edressi, H., Anazi, A., Altayeb, N., Ahmed, M., Alansary, K., Abduljaleel, Z., Kratz, A., Beguin, P., Poulain, S., Kaneko, M., Takahiko, C., Matsunaga, A., Kato, S., Suzuki, A., Bertin, N., Lassmann, T., Vigot, R., Carninci, P., Plessy, C., Launey, T., Graur, D., Lee, D., Kapoor, A., Chakravarti, A., Friis-Nielsen, J., Izarzugaza, J., Brunak, S., Chakraborty, A., Basak, J., Mukhopadhyay, A., Soibam, B., Das, D., Biswas, N., Das, S., Sarkar, S., Maitra, A., Panda, C., Majumder, P., Morsy, H., Gaballah, A., Samir, M., Shamseya, M., Mahrous, H., Ghazal, A., Arafat, W., Hashish, M., Gruber, J., Jaeger, N., Snyder, M., Patel, K., Bowman, S., Davis, T., Kraushaar, D., Emerman, A., Russello, S., Henig, N., Hendrickson, C., Zhang, K., Rodriguez-Dorantes, M., Cruz-Hernandez, C., Garcia-Tobilla, C., Solorzano-Rosales, S., Jäger, N., Chen, J., Haile, R., Hitchins, M., Brooks, J., Snyder, M., Jiménez-Morales, S., Ramírez, M., Nuñez, J., Bekker, V., Leal, Y., Jiménez, E., Medina, A., Hidalgo, A., Mejía, J., Halytskiy, V., Naggert, J., Collin, G., DeMauro, K., Hanusek, R., Nishina, P., Belhassa, K., Belhassan, K., Bouguenouch, L., Samri, I., Sayel, H., moufid, FZ., El Bouchikhi, I., Trhanint, S., Hamdaoui, H., Elotmani, I., Khtiri, I., Kettani, O., Quibibo, L., Ahagoud, M., Abbassi, M., Ouldim, K., Marusin, A., Kornetov, A., Swarovskaya, M., Vagaiceva, K., Stepanov, V., De La Paz, E., Sy, R., Nevado, J., Reganit, P., Santos, L., Magno, J., Punzalan, F., Ona, D., Llanes, E., Santos-Cortes, R., Tiongco, R., Aherrera, J., Abrahan, L., Pagauitan-Alan, P., Morelli, K., Domire, J., Pyne, N., Harper, S., Burgess, R., Zhalbinova, M., Akilzhanova, A., Rakhimova, S., Bekbosynova, M., Myrzakhmetova, S., Gari, M., Dallol, A., Alsehli, H., Gari, A., Gari, M., Abuzenadah, A., Thomas, M., Sukhai, M., Garg, S., Misyura, M., Zhang, T., Schuh, A., Stockley, T., Kamel-Reid, S., Sherry, S., Xiao, C., Slotta, D., Rodarmer, K., Feolo, M., Kimelman, M., Godynskiy, G., O’Sullivan, C., Yaschenko, E., Xiao, C., Yaschenko, E., Sherry, S., Rangel-Escareño, C., Rueda-Zarate, H., Tayubi, I., Mohammed, R., Ahmed, I., Ahmed, T., Seth, S., Amin, S., Song, X., Mao, X., Sun, H., Verhaak, R., Futreal, A., Zhang, J., Whiite, S., Chiang, T., English, A., Farek, J., Kahn, Z., Salerno, W., Veeraraghavan, N., Boerwinkle, E., Gibbs, R., Kasukawa, T., Lizio, M., Harshbarger, J., Hisashi, S., Severin, J., Imad, A., Sahin, S., Freeman, T., Baillie, K., Sandelin, A., Carninci, P., Forrest, A., Kawaji, H., Salerno, W., English, A., Shekar, S., Mangubat, A., Bruestle, J., Boerwinkle, E., Gibbs, R., Salem, A., Ali, M., Ibrahim, A., Ibrahim, M., Barrera, H., Garza, L., Torres, J., Barajas, V., Ulloa-Aguirre, A., Kershenobich, D., Mortaji, Shahroj, Guizar, Pedro, Loera, Eliezer, Moreno, Karen, De León, Adriana, Monsiváis, Daniela, Gómez, Jackeline, Cardiel, Raquel, Fernandez-Lopez, J., Bonifaz-Peña, V., Rangel-Escareño, C., Hidalgo-Miranda, A., Contreras, A., Polfus, L., Wang, X., Philip, V., Carter, G., Abuzenadah, A., Gari, M., Turki, R., Dallol, A., Uyar, A., Kaygun, A., Zaman, S., Marquez, E., George, J., Ucar, D., Hendrickson, C., Emerman, A., Kraushaar, D., Bowman, S., Henig, N., Davis, T., Russello, S., Patel, K., Starr, D., Baird, M., Kirkpatrick, B., Sheets, K., Nitsche, R., Prieto-Lafuente, L., Landrum, M., Lee, J., Rubinstein, W., Maglott, D., Thavanati, P., de Dios, A., Hernandez, R., Aldrate, M., Mejia, M., Kanala, K., Abduljaleel, Z., Khan, W., Al-Allaf, F., Athar, M., Taher, M., Shahzad, N., Bouazzaoui, A., Huber, E., Dan, A., Al-Allaf, F., Herr, W., Sprotte, G., Köstler, J., Hiergeist, A., Gessner, A., Andreesen, R., Holler, E., Al-Allaf, F., Alashwal, A., Abduljaleel, Z., Taher, M., Bouazzaoui, A., Abalkhail, H., Al-Allaf, A., Bamardadh, R., Athar, M., Filiptsova, O., Kobets, M., Kobets, Y., Burlaka, I., Timoshyna, I., Filiptsova, O., Kobets, M., Kobets, Y., Burlaka, I., Timoshyna, I., Filiptsova, O., Kobets, M., Kobets, Y., Burlaka, I., Timoshyna, I., Al-allaf, F., Mohiuddin, M., Zainularifeen, A., Mohammed, A., Abalkhail, H., Owaidah, T., and Bouazzaoui, A.
- Abstract
O1 The metabolomics approach to autism: identification of biomarkers for early detection of autism spectrum disorder A. K. Srivastava, Y. Wang, R. Huang, C. Skinner, T. Thompson, L. Pollard, T. Wood, F. Luo, R. Stevenson O2 Phenome-wide association study for smoking- and drinking-associated genes in 26,394 American women with African, Asian, European, and Hispanic descents R. Polimanti, J. Gelernter O3 Effects of prenatal environment, genotype and DNA methylation on birth weight and subsequent postnatal outcomes: findings from GUSTO, an Asian birth cohort X. Lin, I. Y. Lim, Y. Wu, A. L. Teh, L. Chen, I. M. Aris, S. E. Soh, M. T. Tint, J. L. MacIsaac, F. Yap, K. Kwek, S. M. Saw, M. S. Kobor, M. J. Meaney, K. M. Godfrey, Y. S. Chong, J. D. Holbrook, Y. S. Lee, P. D. Gluckman, N. Karnani, GUSTO study group O4 High-throughput identification of specific qt interval modulating enhancers at the SCN5A locus A. Kapoor, D. Lee, A. Chakravarti O5 Identification of extracellular matrix components inducing cancer cell migration in the supernatant of cultivated mesenchymal stem cells C. Maercker, F. Graf, M. Boutros O6 Single cell allele specific expression (ASE) IN T21 and common trisomies: a novel approach to understand DOWN syndrome and other aneuploidies G. Stamoulis, F. Santoni, P. Makrythanasis, A. Letourneau, M. Guipponi, N. Panousis, M. Garieri, P. Ribaux, E. Falconnet, C. Borel, S. E. Antonarakis O7 Role of microRNA in LCL to IPSC reprogramming S. Kumar, J. Curran, J. Blangero O8 Multiple enhancer variants disrupt gene regulatory network in Hirschsprung disease S. Chatterjee, A. Kapoor, J. Akiyama, D. Auer, C. Berrios, L. Pennacchio, A. Chakravarti O9 Metabolomic profiling for the diagnosis of neurometabolic disorders T. R. Donti, G. Cappuccio, M. Miller, P. Atwal, A. Kennedy, A. Cardon, C. Bacino, L. Emrick, J. Hertecant, F. Baumer, B. Porter, M. Bainbridge, P. Bonnen, B. Graham, R. Sutton, Q. Sun, S. Elsea O10 A novel causal methylation network approach to Alzheimer’s disease Z. Hu, P. Wang, Y. Zhu, J. Zhao, M. Xiong, David A Bennett O11 A microRNA signature identifies subtypes of triple-negative breast cancer and reveals MIR-342-3P as regulator of a lactate metabolic pathway A. Hidalgo-Miranda, S. Romero-Cordoba, S. Rodriguez-Cuevas, R. Rebollar-Vega, E. Tagliabue, M. Iorio, E. D’Ippolito, S. Baroni O12 Transcriptome analysis identifies genes, enhancer RNAs and repetitive elements that are recurrently deregulated across multiple cancer types B. Kaczkowski, Y. Tanaka, H. Kawaji, A. Sandelin, R. Andersson, M. Itoh, T. Lassmann, the FANTOM5 consortium, Y. Hayashizaki, P. Carninci, A. R. R. Forrest O13 Elevated mutation and widespread loss of constraint at regulatory and architectural binding sites across 11 tumour types C. A. Semple O14 Exome sequencing provides evidence of pathogenicity for genes implicated in colorectal cancer E. A. Rosenthal, B. Shirts, L. Amendola, C. Gallego, M. Horike-Pyne, A. Burt, P. Robertson, P. Beyers, C. Nefcy, D. Veenstra, F. Hisama, R. Bennett, M. Dorschner, D. Nickerson, J. Smith, K. Patterson, D. Crosslin, R. Nassir, N. Zubair, T. Harrison, U. Peters, G. Jarvik, NHLBI GO Exome Sequencing Project O15 The tandem duplicator phenotype as a distinct genomic configuration in cancer F. Menghi, K. Inaki, X. Woo, P. Kumar, K. Grzeda, A. Malhotra, H. Kim, D. Ucar, P. Shreckengast, K. Karuturi, J. Keck, J. Chuang, E. T. Liu O16 Modeling genetic interactions associated with molecular subtypes of breast cancer B. Ji, A. Tyler, G. Ananda, G. Carter O17 Recurrent somatic mutation in the MYC associated factor X in brain tumors H. Nikbakht, M. Montagne, M. Zeinieh, A. Harutyunyan, M. Mcconechy, N. Jabado, P. Lavigne, J. Majewski O18 Predictive biomarkers to metastatic pancreatic cancer treatment J. B. Goldstein, M. Overman, G. Varadhachary, R. Shroff, R. Wolff, M. Javle, A. Futreal, D. Fogelman O19 DDIT4 gene expression as a prognostic marker in several malignant tumors L. Bravo, W. Fajardo, H. Gomez, C. Castaneda, C. Rolfo, J. A. Pinto O20 Spatial organization of the genome and genomic alterations in human cancers K. C. Akdemir, L. Chin, A. Futreal, ICGC PCAWG Structural Alterations Group O21 Landscape of targeted therapies in solid tumors S. Patterson, C. Statz, S. Mockus O22 Genomic analysis reveals novel drivers and progression pathways in skin basal cell carcinoma S. N. Nikolaev, X. I. Bonilla, L. Parmentier, B. King, F. Bezrukov, G. Kaya, V. Zoete, V. Seplyarskiy, H. Sharpe, T. McKee, A. Letourneau, P. Ribaux, K. Popadin, N. Basset-Seguin, R. Ben Chaabene, F. Santoni, M. Andrianova, M. Guipponi, M. Garieri, C. Verdan, K. Grosdemange, O. Sumara, M. Eilers, I. Aifantis, O. Michielin, F. de Sauvage, S. Antonarakis O23 Identification of differential biomarkers of hepatocellular carcinoma and cholangiocarcinoma via transcriptome microarray meta-analysis S. Likhitrattanapisal O24 Clinical validity and actionability of multigene tests for hereditary cancers in a large multi-center study S. Lincoln, A. Kurian, A. Desmond, S. Yang, Y. Kobayashi, J. Ford, L. Ellisen O25 Correlation with tumor ploidy status is essential for correct determination of genome-wide copy number changes by SNP array T. L. Peters, K. R. Alvarez, E. F. Hollingsworth, D. H. Lopez-Terrada O26 Nanochannel based next-generation mapping for interrogation of clinically relevant structural variation A. Hastie, Z. Dzakula, A. W. Pang, E. T. Lam, T. Anantharaman, M. Saghbini, H. Cao, BioNano Genomics O27 Mutation spectrum in a pulmonary arterial hypertension (PAH) cohort and identification of associated truncating mutations in TBX4 C. Gonzaga-Jauregui, L. Ma, A. King, E. Berman Rosenzweig, U. Krishnan, J. G. Reid, J. D. Overton, F. Dewey, W. K. Chung O28 NORTH CAROLINA macular dystrophy (MCDR1): mutations found affecting PRDM13 K. Small, A. DeLuca, F. Cremers, R. A. Lewis, V. Puech, B. Bakall, R. Silva-Garcia, K. Rohrschneider, M. Leys, F. S. Shaya, E. Stone O29 PhenoDB and genematcher, solving unsolved whole exome sequencing data N. L. Sobreira, F. Schiettecatte, H. Ling, E. Pugh, D. Witmer, K. Hetrick, P. Zhang, K. Doheny, D. Valle, A. Hamosh O30 Baylor-Johns Hopkins Center for Mendelian genomics: a four year review S. N. Jhangiani, Z. Coban Akdemir, M. N. Bainbridge, W. Charng, W. Wiszniewski, T. Gambin, E. Karaca, Y. Bayram, M. K. Eldomery, J. Posey, H. Doddapaneni, J. Hu, V. R. Sutton, D. M. Muzny, E. A. Boerwinkle, D. Valle, J. R. Lupski, R. A. Gibbs O31 Using read overlap assembly to accurately identify structural genetic differences in an ashkenazi jewish trio S. Shekar, W. Salerno, A. English, A. Mangubat, J. Bruestle O32 Legal interoperability: a sine qua non for international data sharing A. Thorogood, B. M. Knoppers, Global Alliance for Genomics and Health - Regulatory and Ethics Working Group O33 High throughput screening platform of competent sineups: that can enhance translation activities of therapeutic target H. Takahashi, K. R. Nitta, A. Kozhuharova, A. M. Suzuki, H. Sharma, D. Cotella, C. Santoro, S. Zucchelli, S. Gustincich, P. Carninci O34 The undiagnosed diseases network international (UDNI): clinical and laboratory research to meet patient needs J. J. Mulvihill, G. Baynam, W. Gahl, S. C. Groft, K. Kosaki, P. Lasko, B. Melegh, D. Taruscio O36 Performance of computational algorithms in pathogenicity predictions for activating variants in oncogenes versus loss of function mutations in tumor suppressor genes R. Ghosh, S. Plon O37 Identification and electronic health record incorporation of clinically actionable pharmacogenomic variants using prospective targeted sequencing S. Scherer, X. Qin, R. Sanghvi, K. Walker, T. Chiang, D. Muzny, L. Wang, J. Black, E. Boerwinkle, R. Weinshilboum, R. Gibbs O38 Melanoma reprogramming state correlates with response to CTLA-4 blockade in metastatic melanoma T. Karpinets, T. Calderone, K. Wani, X. Yu, C. Creasy, C. Haymaker, M. Forget, V. Nanda, J. Roszik, J. Wargo, L. Haydu, X. Song, A. Lazar, J. Gershenwald, M. Davies, C. Bernatchez, J. Zhang, A. Futreal, S. Woodman O39 Data-driven refinement of complex disease classification from integration of heterogeneous functional genomics data in GeneWeaver E. J. Chesler, T. Reynolds, J. A. Bubier, C. Phillips, M. A. Langston, E. J. Baker O40 A general statistic framework for genome-based disease risk prediction M. Xiong, L. Ma, N. Lin, C. Amos O41 Integrative large-scale causal network analysis of imaging and genomic data and its application in schizophrenia studies N. Lin, P. Wang, Y. Zhu, J. Zhao, V. Calhoun, M. Xiong O42 Big data and NGS data analysis: the cloud to the rescue O. Dobretsberger, M. Egger, F. Leimgruber O43 Cpipe: a convergent clinical exome pipeline specialised for targeted sequencing S. Sadedin, A. Oshlack, Melbourne Genomics Health Alliance O44 A Bayesian classification of biomedical images using feature extraction from deep neural networks implemented on lung cancer data V. A. A. Antonio, N. Ono, Clark Kendrick C. Go O45 MAV-SEQ: an interactive platform for the Management, Analysis, and Visualization of sequence data Z. Ahmed, M. Bolisetty, S. Zeeshan, E. Anguiano, D. Ucar O47 Allele specific enhancer in EPAS1 intronic regions may contribute to high altitude adaptation of Tibetans C. Zeng, J. Shao O48 Nanochannel based next-generation mapping for structural variation detection and comparison in trios and populations H. Cao, A. Hastie, A. W. Pang, E. T. Lam, T. Liang, K. Pham, M. Saghbini, Z. Dzakula O49 Archaic introgression in indigenous populations of Malaysia revealed by whole genome sequencing Y. Chee-Wei, L. Dongsheng, W. Lai-Ping, D. Lian, R. O. Twee Hee, Y. Yunus, F. Aghakhanian, S. S. Mokhtar, C. V. Lok-Yung, J. Bhak, M. Phipps, X. Shuhua, T. Yik-Ying, V. Kumar, H. Boon-Peng O50 Breast and ovarian cancer prevention: is it time for population-based mutation screening of high risk genes? I. Campbell, M.-A. Young, P. James, Lifepool O53 Comprehensive coverage from low DNA input using novel NGS library preparation methods for WGS and WGBS C. Schumacher, S. Sandhu, T. Harkins, V. Makarov O54 Methods for large scale construction of robust PCR-free libraries for sequencing on Illumina HiSeqX platform H. DoddapaneniR. Glenn, Z. Momin, B. Dilrukshi, H. Chao, Q. Meng, B. Gudenkauf, R. Kshitij, J. Jayaseelan, C. Nessner, S. Lee, K. Blankenberg, L. Lewis, J. Hu, Y. Han, H. Dinh, S. Jireh, K. Walker, E. Boerwinkle, D. Muzny, R. Gibbs O55 Rapid capture methods for clinical sequencing J. Hu, K. Walker, C. Buhay, X. Liu, Q. Wang, R. Sanghvi, H. Doddapaneni, Y. Ding, N. Veeraraghavan, Y. Yang, E. Boerwinkle, A. L. Beaudet, C. M. Eng, D. M. Muzny, R. A. Gibbs O56 A diploid personal human genome model for better genomes from diverse sequence data K. C. C. Worley, Y. Liu, D. S. T. Hughes, S. C. Murali, R. A. Harris, A. C. English, X. Qin, O. A. Hampton, P. Larsen, C. Beck, Y. Han, M. Wang, H. Doddapaneni, C. L. Kovar, W. J. Salerno, A. Yoder, S. Richards, J. Rogers, J. R. Lupski, D. M. Muzny, R. A. Gibbs O57 Development of PacBio long range capture for detection of pathogenic structural variants Q. Meng, M. Bainbridge, M. Wang, H. Doddapaneni, Y. Han, D. Muzny, R. Gibbs O58 Rhesus macaques exhibit more non-synonymous variation but greater impact of purifying selection than humans R. A. Harris, M. Raveenedran, C. Xue, M. Dahdouli, L. Cox, G. Fan, B. Ferguson, J. Hovarth, Z. Johnson, S. Kanthaswamy, M. Kubisch, M. Platt, D. Smith, E. Vallender, R. Wiseman, X. Liu, J. Below, D. Muzny, R. Gibbs, F. Yu, J. Rogers O59 Assessing RNA structure disruption induced by single-nucleotide variation J. Lin, Y. Zhang, Z. Ouyang P1 A meta-analysis of genome-wide association studies of mitochondrial dna copy number A. Moore, Z. Wang, J. Hofmann, M. Purdue, R. Stolzenberg-Solomon, S. Weinstein, D. Albanes, C.-S. Liu, W.-L. Cheng, T.-T. Lin, Q. Lan, N. Rothman, S. Berndt P2 Missense polymorphic genetic combinations underlying down syndrome susceptibility E. S. Chen P4 The evaluation of alteration of ELAM-1 expression in the endometriosis patients H. Bahrami, A. Khoshzaban, S. Heidari Keshal P5 Obesity and the incidence of apolipoprotein E polymorphisms in an assorted population from Saudi Arabia population K. K. R. Alharbi P6 Genome-associated personalized antithrombotical therapy for patients with high risk of thrombosis and bleeding M. Zhalbinova, A. Akilzhanova, S. Rakhimova, M. Bekbosynova, S. Myrzakhmetova P7 Frequency of Xmn1 polymorphism among sickle cell carrier cases in UAE population M. Matar P8 Differentiating inflammatory bowel diseases by using genomic data: dimension of the problem and network organization N. Mili, R. Molinari, Y. Ma, S. Guerrier P9 Vulnerability of genetic variants to the risk of autism among Saudi children N. Elhawary, M. Tayeb, N. Bogari, N. Qotb P10 Chromatin profiles from ex vivo purified dopaminergic neurons establish a promising model to support studies of neurological function and dysfunction S. A. McClymont, P. W. Hook, L. A. Goff, A. McCallion P11 Utilization of a sensitized chemical mutagenesis screen to identify genetic modifiers of retinal dysplasia in homozygous Nr2e3rd7mice Y. Kong, J. R. Charette, W. L. Hicks, J. K. Naggert, L. Zhao, P. M. Nishina P12 Ion torrent next generation sequencing of recessive polycystic kidney disease in Saudi patients B. M. Edrees, M. Athar, F. A. Al-Allaf, M. M. Taher, W. Khan, A. Bouazzaoui, N. A. Harbi, R. Safar, H. Al-Edressi, A. Anazi, N. Altayeb, M. A. Ahmed, K. Alansary, Z. Abduljaleel P13 Digital expression profiling of Purkinje neurons and dendrites in different subcellular compartments A. Kratz, P. Beguin, S. Poulain, M. Kaneko, C. Takahiko, A. Matsunaga, S. Kato, A. M. Suzuki, N. Bertin, T. Lassmann, R. Vigot, P. Carninci, C. Plessy, T. Launey P14 The evolution of imperfection and imperfection of evolution: the functional and functionless fractions of the human genome D. Graur P16 Species-independent identification of known and novel recurrent genomic entities in multiple cancer patients J. Friis-Nielsen, J. M. Izarzugaza, S. Brunak P18 Discovery of active gene modules which are densely conserved across multiple cancer types reveal their prognostic power and mutually exclusive mutation patterns B. S. Soibam P19 Whole exome sequencing of dysplastic leukoplakia tissue indicates sequential accumulation of somatic mutations from oral precancer to cancer D. Das, N. Biswas, S. Das, S. Sarkar, A. Maitra, C. Panda, P. Majumder P21 Epigenetic mechanisms of carcinogensis by hereditary breast cancer genes J. J. Gruber, N. Jaeger, M. Snyder P22 RNA direct: a novel RNA enrichment strategy applied to transcripts associated with solid tumors K. Patel, S. Bowman, T. Davis, D. Kraushaar, A. Emerman, S. Russello, N. Henig, C. Hendrickson P23 RNA sequencing identifies gene mutations for neuroblastoma K. Zhang P24 Participation of SFRP1 in the modulation of TMPRSS2-ERG fusion gene in prostate cancer cell lines M. Rodriguez-Dorantes, C. D. Cruz-Hernandez, C. D. P. Garcia-Tobilla, S. Solorzano-Rosales P25 Targeted Methylation Sequencing of Prostate Cancer N. Jäger, J. Chen, R. Haile, M. Hitchins, J. D. Brooks, M. Snyder P26 Mutant TPMT alleles in children with acute lymphoblastic leukemia from México City and Yucatán, Mexico S. Jiménez-Morales, M. Ramírez, J. Nuñez, V. Bekker, Y. Leal, E. Jiménez, A. Medina, A. Hidalgo, J. Mejía P28 Genetic modifiers of Alström syndrome J. Naggert, G. B. Collin, K. DeMauro, R. Hanusek, P. M. Nishina P31 Association of genomic variants with the occurrence of angiotensin-converting-enzyme inhibitor (ACEI)-induced coughing among Filipinos E. M. Cutiongco De La Paz, R. Sy, J. Nevado, P. Reganit, L. Santos, J. D. Magno, F. E. Punzalan , D. Ona , E. Llanes, R. L. Santos-Cortes , R. Tiongco, J. Aherrera, L. Abrahan, P. Pagauitan-Alan; Philippine Cardiogenomics Study Group P32 The use of “humanized” mouse models to validate disease association of a de novo GARS variant and to test a novel gene therapy strategy for Charcot-Marie-Tooth disease type 2D K. H. Morelli, J. S. Domire, N. Pyne, S. Harper, R. Burgess P34 Molecular regulation of chondrogenic human induced pluripotent stem cells M. A. Gari, A. Dallol, H. Alsehli, A. Gari, M. Gari, A. Abuzenadah P35 Molecular profiling of hematologic malignancies: implementation of a variant assessment algorithm for next generation sequencing data analysis and clinical reporting M. Thomas, M. Sukhai, S. Garg, M. Misyura, T. Zhang, A. Schuh, T. Stockley, S. Kamel-Reid P36 Accessing genomic evidence for clinical variants at NCBI S. Sherry, C. Xiao, D. Slotta, K. Rodarmer, M. Feolo, M. Kimelman, G. Godynskiy, C. O’Sullivan, E. Yaschenko P37 NGS-SWIFT: a cloud-based variant analysis framework using control-accessed sequencing data from DBGAP/SRA C. Xiao, E. Yaschenko, S. Sherry P38 Computational assessment of drug induced hepatotoxicity through gene expression profiling C. Rangel-Escareño, H. Rueda-Zarate P40 Flowr: robust and efficient pipelines using a simple language-agnostic approach;ultraseq; fast modular pipeline for somatic variation calling using flowr S. Seth, S. Amin, X. Song, X. Mao, H. Sun, R. G. Verhaak, A. Futreal, J. Zhang P41 Applying “Big data” technologies to the rapid analysis of heterogenous large cohort data S. J. Whiite, T. Chiang, A. English, J. Farek, Z. Kahn, W. Salerno, N. Veeraraghavan, E. Boerwinkle, R. Gibbs P42 FANTOM5 web resource for the large-scale genome-wide transcription start site activity profiles of wide-range of mammalian cells T. Kasukawa, M. Lizio, J. Harshbarger, S. Hisashi, J. Severin, A. Imad, S. Sahin, T. C. Freeman, K. Baillie, A. Sandelin, P. Carninci, A. R. R. Forrest, H. Kawaji, The FANTOM Consortium P43 Rapid and scalable typing of structural variants for disease cohorts W. Salerno, A. English, S. N. Shekar, A. Mangubat, J. Bruestle, E. Boerwinkle, R. A. Gibbs P44 Polymorphism of glutathione S-transferases and sulphotransferases genes in an Arab population A. H. Salem, M. Ali, A. Ibrahim, M. Ibrahim P46 Genetic divergence of CYP3A5*3 pharmacogenomic marker for native and admixed Mexican populations J. C. Fernandez-Lopez, V. Bonifaz-Peña, C. Rangel-Escareño, A. Hidalgo-Miranda, A. V. Contreras P47 Whole exome sequence meta-analysis of 13 white blood cell, red blood cell, and platelet traits L. Polfus, CHARGE and NHLBI Exome Sequence Project Working Groups P48 Association of adipoq gene with type 2 diabetes and related phenotypes in african american men and women: The jackson heart study S. Davis, R. Xu, S. Gebeab, P Riestra, A Gaye, R. Khan, J. Wilson, A. Bidulescu P49 Common variants in casr gene are associated with serum calcium levels in koreans S. H. Jung, N. Vinayagamoorthy, S. H. Yim, Y. J. Chung P50 Inference of multiple-wave population admixture by modeling decay of linkage disequilibrium with multiple exponential functions Y. Zhou, S. Xu P51 A Bayesian framework for generalized linear mixed models in genome-wide association studies X. Wang, V. Philip, G. Carter P52 Targeted sequencing approach for the identification of the genetic causes of hereditary hearing impairment A. A. Abuzenadah, M. Gari, R. Turki, A. Dallol P53 Identification of enhancer sequences by ATAC-seq open chromatin profiling A. Uyar, A. Kaygun, S. Zaman, E. Marquez, J. George, D. Ucar P54 Direct enrichment for the rapid preparation of targeted NGS libraries C. L. Hendrickson, A. Emerman, D. Kraushaar, S. Bowman, N. Henig, T. Davis, S. Russello, K. Patel P56 Performance of the Agilent D5000 and High Sensitivity D5000 ScreenTape assays for the Agilent 4200 Tapestation System R. Nitsche, L. Prieto-Lafuente P57 ClinVar: a multi-source archive for variant interpretation M. Landrum, J. Lee, W. Rubinstein, D. Maglott P59 Association of functional variants and protein physical interactions of human MUTY homolog linked with familial adenomatous polyposis and colorectal cancer syndrome Z. Abduljaleel, W. Khan, F. A. Al-Allaf, M. Athar , M. M. Taher, N. Shahzad P60 Modification of the microbiom constitution in the gut using chicken IgY antibodies resulted in a reduction of acute graft-versus-host disease after experimental bone marrow transplantation A. Bouazzaoui, E. Huber, A. Dan, F. A. Al-Allaf, W. Herr, G. Sprotte, J. Köstler, A. Hiergeist, A. Gessner, R. Andreesen, E. Holler P61 Compound heterozygous mutation in the LDLRgene in Saudi patients suffering severe hypercholesterolemia F. Al-Allaf, A. Alashwal, Z. Abduljaleel, M. Taher, A. Bouazzaoui, H. Abalkhail, A. Al-Allaf, R. Bamardadh, M. Athar
- Published
- 2016
- Full Text
- View/download PDF
38. Human genome meeting 2016
- Author
-
Srivastava, A. K., Wang, Y., Huang, R., Skinner, C., Thompson, T., Pollard, L., Wood, T., Luo, F., Stevenson, R., Polimanti, R., Gelernter, J., Lin, X., Lim, I. Y., Wu, Y., Teh, A. L., Chen, L., Aris, I. M., Soh, S. E., Tint, M. T., MacIsaac, J. L., Yap, F., Kwek, K., Saw, S. M., Kobor, M. S., Meaney, M. J., Godfrey, K. M., Chong, Y. S., Holbrook, J. D., Lee, Y. S., Gluckman, P. D., Karnani, N., Kapoor, A., Lee, D., Chakravarti, A., Maercker, C., Graf, F., Boutros, M., Stamoulis, G., Santoni, F., Makrythanasis, P., Letourneau, A., Guipponi, M., Panousis, N., Garieri, M., Ribaux, P., Falconnet, E., Borel, C., Antonarakis, S. E., Kumar, S., Curran, J., Blangero, J., Chatterjee, S., Akiyama, J., Auer, D., Berrios, C., Pennacchio, L., Donti, T. R., Cappuccio, G., Miller, M., Atwal, P., Kennedy, A., Cardon, A., Bacino, C., Emrick, L., Hertecant, J., Baumer, F., Porter, B., Bainbridge, M., Bonnen, P., Graham, B., Sutton, R., Sun, Q., Elsea, S., Hu, Z., Wang, P., Zhu, Y., Zhao, J., Xiong, M., Bennett, David A., Hidalgo-Miranda, A., Romero-Cordoba, S., Rodriguez-Cuevas, S., Rebollar-Vega, R., Tagliabue, E., Iorio, M., D’Ippolito, E., Baroni, S., Kaczkowski, B., Tanaka, Y., Kawaji, H., Sandelin, A., Andersson, R., Itoh, M., Lassmann, T., Hayashizaki, Y., Carninci, P., Forrest, A. R. R., Semple, C. A., Rosenthal, E. A., Shirts, B., Amendola, L., Gallego, C., Horike-Pyne, M., Burt, A., Robertson, P., Beyers, P., Nefcy, C., Veenstra, D., Hisama, F., Bennett, R., Dorschner, M., Nickerson, D., Smith, J., Patterson, K., Crosslin, D., Nassir, R., Zubair, N., Harrison, T., Peters, U., Jarvik, G., Menghi, F., Inaki, K., Woo, X., Kumar, P., Grzeda, K., Malhotra, A., Kim, H., Ucar, D., Shreckengast, P., Karuturi, K., Keck, J., Chuang, J., Liu, E. T., Ji, B., Tyler, A., Ananda, G., Carter, G., Nikbakht, H., Montagne, M., Zeinieh, M., Harutyunyan, A., Mcconechy, M., Jabado, N., Lavigne, P., Majewski, J., Goldstein, J. B., Overman, M., Varadhachary, G., Shroff, R., Wolff, R., Javle, M., Futreal, A., Fogelman, D., Bravo, L., Fajardo, W., Gomez, H., Castaneda, C., Rolfo, C., Pinto, J. A., Akdemir, K. C., Chin, L., Patterson, S., Statz, C., Mockus, S., Nikolaev, S. N., Bonilla, X. I., Parmentier, L., King, B., Bezrukov, F., Kaya, G., Zoete, V., Seplyarskiy, V., Sharpe, H., McKee, T., Popadin, K., Basset-Seguin, N., Chaabene, R. Ben, Andrianova, M., Verdan, C., Grosdemange, K., Sumara, O., Eilers, M., Aifantis, I., Michielin, O., de Sauvage, F., Antonarakis, S., Likhitrattanapisal, S., Lincoln, S., Kurian, A., Desmond, A., Yang, S., Kobayashi, Y., Ford, J., Ellisen, L., Peters, T. L., Alvarez, K. R., Hollingsworth, E. F., Lopez-Terrada, D. H., Hastie, A., Dzakula, Z., Pang, A. W., Lam, E. T., Anantharaman, T., Saghbini, M., Cao, H., Gonzaga-Jauregui, C., Ma, L., King, A., Rosenzweig, E. Berman, Krishnan, U., Reid, J. G., Overton, J. D., Dewey, F., Chung, W. K., Small, K., DeLuca, A., Cremers, F., Lewis, R. A., Puech, V., Bakall, B., Silva-Garcia, R., Rohrschneider, K., Leys, M., Shaya, F. S., Stone, E., Sobreira, N. L., Schiettecatte, F., Ling, H., Pugh, E., Witmer, D., Hetrick, K., Zhang, P., Doheny, K., Valle, D., Hamosh, A., Jhangiani, S. N., Akdemir, Z. Coban, Bainbridge, M. N., Charng, W., Wiszniewski, W., Gambin, T., Karaca, E., Bayram, Y., Eldomery, M. K., Posey, J., Doddapaneni, H., Hu, J., Sutton, V. R., Muzny, D. M., Boerwinkle, E. A., Lupski, J. R., Gibbs, R. A., Shekar, S., Salerno, W., English, A., Mangubat, A., Bruestle, J., Thorogood, A., Knoppers, B. M., Takahashi, H., Nitta, K. R., Kozhuharova, A., Suzuki, A. M., Sharma, H., Cotella, D., Santoro, C., Zucchelli, S., Gustincich, S., Mulvihill, J. J., Baynam, G., Gahl, W., Groft, S. C., Kosaki, K., Lasko, P., Melegh, B., Taruscio, D., Ghosh, R., Plon, S., Scherer, S., Qin, X., Sanghvi, R., Walker, K., Chiang, T., Muzny, D., Wang, L., Black, J., Boerwinkle, E., Weinshilboum, R., Gibbs, R., Karpinets, T., Calderone, T., Wani, K., Yu, X., Creasy, C., Haymaker, C., Forget, M., Nanda, V., Roszik, J., Wargo, J., Haydu, L., Song, X., Lazar, A., Gershenwald, J., Davies, M., Bernatchez, C., Zhang, J., Woodman, S., Chesler, E. J., Reynolds, T., Bubier, J. A., Phillips, C., Langston, M. A., Baker, E. J., Lin, N., Amos, C., Calhoun, V., Dobretsberger, O., Egger, M., Leimgruber, F., Sadedin, S., Oshlack, A., Antonio, V. A. A., Ono, N., Ahmed, Z., Bolisetty, M., Zeeshan, S., Anguiano, E., Sarkar, A., Nandineni, M. R., Zeng, C., Shao, J., Liang, T., Pham, K., Chee-Wei, Y., Dongsheng, L., Lai-Ping, W., Lian, D., Hee, R. O. Twee, Yunus, Y., Aghakhanian, F., Mokhtar, S. S., Lok-Yung, C. V., Bhak, J., Phipps, M., Shuhua, X., Yik-Ying, T., Kumar, V., Boon-Peng, H., Campbell, I., Young, M. -A., James, P., Rain, M., Mohammad, G., Kukreti, R., Pasha, Q., Akilzhanova, A. R., Guelly, C., Abilova, Z., Rakhimova, S., Akhmetova, A., Kairov, U., Trajanoski, S., Zhumadilov, Z., Bekbossynova, M., Schumacher, C., Sandhu, S., Harkins, T., Makarov, V., Glenn, R., Momin, Z., Dilrukshi, B., Chao, H., Meng, Q., Gudenkauf, B., Kshitij, R., Jayaseelan, J., Nessner, C., Lee, S., Blankenberg, K., Lewis, L., Han, Y., Dinh, H., Jireh, S., Buhay, C., Liu, X., Wang, Q., Ding, Y., Veeraraghavan, N., Yang, Y., Beaudet, A. L., Eng, C. M., Worley, K. C. C., Liu, Y., Hughes, D. S. T., Murali, S. C., Harris, R. A., English, A. C., Hampton, O. A., Larsen, P., Beck, C., Wang, M., Kovar, C. L., Salerno, W. J., Yoder, A., Richards, S., Rogers, J., Raveenedran, M., Xue, C., Dahdouli, M., Cox, L., Fan, G., Ferguson, B., Hovarth, J., Johnson, Z., Kanthaswamy, S., Kubisch, M., Platt, M., Smith, D., Vallender, E., Wiseman, R., Below, J., Yu, F., Lin, J., Zhang, Y., Ouyang, Z., Moore, A., Wang, Z., Hofmann, J., Purdue, M., Stolzenberg-Solomon, R., Weinstein, S., Albanes, D., Liu, C. S., Cheng, W. L., Lin, T. T., Lan, Q., Rothman, N., Berndt, S., Chen, E. S., Bahrami, H., Khoshzaban, A., Keshal, S. Heidari, Alharbi, K. K. R., Zhalbinova, M., Akilzhanova, A., Bekbosynova, M., Myrzakhmetova, S., Matar, M., Mili, N., Molinari, R., Ma, Y., Guerrier, S., Elhawary, N., Tayeb, M., Bogari, N., Qotb, N., McClymont, S. A., Hook, P. W., Goff, L. A., McCallion, A., Kong, Y., Charette, J. R., Hicks, W. L., Naggert, J. K., Zhao, L., Nishina, P. M., Edrees, B. M., Athar, M., Al-Allaf, F. A., Taher, M. M., Khan, W., Bouazzaoui, A., Harbi, N. A., Safar, R., Al-Edressi, H., Anazi, A., Altayeb, N., Ahmed, M. A., Alansary, K., Abduljaleel, Z., Kratz, A., Beguin, P., Poulain, S., Kaneko, M., Takahiko, C., Matsunaga, A., Kato, S., Bertin, N., Vigot, R., Plessy, C., Launey, T., Graur, D., Friis-Nielsen, J., Izarzugaza, J. M., Brunak, S., Chakraborty, A., Basak, J., Mukhopadhyay, A., Soibam, B. S., Das, D., Biswas, N., Das, S., Sarkar, S., Maitra, A., Panda, C., Majumder, P., Morsy, H., Gaballah, A., Samir, M., Shamseya, M., Mahrous, H., Ghazal, A., Arafat, W., Hashish, M., Gruber, J. J., Jaeger, N., Snyder, M., Patel, K., Bowman, S., Davis, T., Kraushaar, D., Emerman, A., Russello, S., Henig, N., Hendrickson, C., Zhang, K., Rodriguez-Dorantes, M., Cruz-Hernandez, C. D., Garcia-Tobilla, C. D. P., Solorzano-Rosales, S., Jäger, N., Chen, J., Haile, R., Hitchins, M., Brooks, J. D., Jiménez-Morales, S., Ramírez, M., Nuñez, J., Bekker, V., Leal, Y., Jiménez, E., Medina, A., Hidalgo, A., Mejía, J., Halytskiy, V., Naggert, J., Collin, G. B., DeMauro, K., Hanusek, R., Belhassa, K., Belhassan, K., Bouguenouch, L., Samri, I., Sayel, H., moufid, FZ., El Bouchikhi, I., Trhanint, S., Hamdaoui, H., Elotmani, I., Khtiri, I., Kettani, O., Quibibo, L., Ahagoud, M., Abbassi, M., Ouldim, K., Marusin, A. V., Kornetov, A. N., Swarovskaya, M., Vagaiceva, K., Stepanov, V., De La Paz, E. M. Cutiongco, Sy, R., Nevado, J., Reganit, P., Santos, L., Magno, J. D., Punzalan, F. E., Ona, D., Llanes, E., Santos-Cortes, R. L., Tiongco, R., Aherrera, J., Abrahan, L., Pagauitan-Alan, P., Morelli, K. H., Domire, J. S., Pyne, N., Harper, S., Burgess, R., Gari, M. A., Dallol, A., Alsehli, H., Gari, A., Gari, M., Abuzenadah, A., Thomas, M., Sukhai, M., Garg, S., Misyura, M., Zhang, T., Schuh, A., Stockley, T., Kamel-Reid, S., Sherry, S., Xiao, C., Slotta, D., Rodarmer, K., Feolo, M., Kimelman, M., Godynskiy, G., O’Sullivan, C., Yaschenko, E., Rangel-Escareño, C., Rueda-Zarate, H., Tayubi, I. A., Mohammed, R., Ahmed, I., Ahmed, T., Seth, S., Amin, S., Mao, X., Sun, H., Verhaak, R. G., Whiite, S. J., Farek, J., Kahn, Z., Kasukawa, T., Lizio, M., Harshbarger, J., Hisashi, S., Severin, J., Imad, A., Sahin, S., Freeman, T. C., Baillie, K., Shekar, S. N., Salem, A. H., Ali, M., Ibrahim, A., Ibrahim, M., Barrera, H. A., Garza, L., Torres, J. A., Barajas, V., Ulloa-Aguirre, A., Kershenobich, D., Mortaji, Shahroj, Guizar, Pedro, Loera, Eliezer, Moreno, Karen, De León, Adriana, Monsiváis, Daniela, Gómez, Jackeline, Cardiel, Raquel, Fernandez-Lopez, J. C., Bonifaz-Peña, V., Contreras, A. V., Polfus, L., Wang, X., Philip, V., Abuzenadah, A. A., Turki, R., Uyar, A., Kaygun, A., Zaman, S., Marquez, E., George, J., Hendrickson, C. L., Starr, D. B., Baird, M., Kirkpatrick, B., Sheets, K., Nitsche, R., Prieto-Lafuente, L., Landrum, M., Lee, J., Rubinstein, W., Maglott, D., Thavanati, P. K. R., de Dios, A. Escoto, Hernandez, R. E. Navarro, Aldrate, M. E. Aguilar, Mejia, M. R. Ruiz, Kanala, K. R. R., Shahzad, N., Huber, E., Dan, A., Herr, W., Sprotte, G., Köstler, J., Hiergeist, A., Gessner, A., Andreesen, R., Holler, E., Al-Allaf, F., Alashwal, A., Taher, M., Abalkhail, H., Al-Allaf, A., Bamardadh, R., Filiptsova, O., Kobets, M., Kobets, Y., Burlaka, I., Timoshyna, I., Kobets, M. N., Al-allaf, F. A., Mohiuddin, M. T., Zainularifeen, A., Mohammed, A., and Owaidah, T.
- Full Text
- View/download PDF
39. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
- Author
-
Cascone, T, primary, William Jr., WN, additional, Weissferdt, A, additional, Leung, CH, additional, Lin, HY, additional, Pataer, A, additional, Godoy, MCB, additional, Carter, BW, additional, Federico, L, additional, Reuben, A, additional, Khan, MAW, additional, Dejima, H, additional, Francisco-Cruz, A, additional, Parra, ER, additional, Solis, LM, additional, Fujimoto, J, additional, Tran, HT, additional, Kalhor, N, additional, Fossella, FV, additional, Mott, FE, additional, Tsao, AS, additional, Blumenschein Jr., G, additional, Le, X, additional, Zhang, J, additional, Skoulidis, F, additional, Kurie, JM, additional, Altan, M, additional, Lu, C, additional, Glisson, BS, additional, Byers, LA, additional, Elamin, YY, additional, Mehran, RJ, additional, Rice, DC, additional, Walsh, GL, additional, Hofstetter, WL, additional, Roth, JA, additional, Antonoff, MB, additional, Kadara, H, additional, Haymaker, C, additional, Bernatchez, C, additional, Ajami, NJ, additional, Jenq, RR, additional, Sharma, P, additional, Allison, JP, additional, Futreal, A, additional, Wargo, JA, additional, Wistuba, II, additional, Swisher, SG, additional, Lee, JJ, additional, Gibbons, DL, additional, Vaporciyan, AA, additional, Heymach, JV, additional, and Sepesi, B, additional
- Full Text
- View/download PDF
40. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer
- Author
-
Federico, L, primary, McGrail, DJ, additional, Bentebibel, SE, additional, Haymaker, C, additional, Ravelli, A, additional, Forget, MA, additional, Karpinets, T, additional, Jiang, P, additional, Reuben, A, additional, Negrao, MV, additional, Li, J, additional, Khairullah, R, additional, Zhang, J, additional, Weissferdt, A, additional, Vaporciyan, AA, additional, Antonoff, MB, additional, Walsh, G, additional, Lin, SY, additional, Futreal, A, additional, Wistuba, I, additional, Roth, J, additional, Byers, LA, additional, Gaudreau, PO, additional, Uraoka, N, additional, Francisco-Cruz, A, additional, Dejima, H, additional, Lazcano, RN, additional, Solis, LM, additional, Parra, ER, additional, Lee, JJ, additional, Swisher, S, additional, Cascone, T, additional, Heymach, JV, additional, Sepesi, B, additional, Gibbons, DL, additional, and Bernatchez, C, additional
- Full Text
- View/download PDF
41. Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer
- Author
-
Kudo, Y, primary, Haymaker, C, additional, Zhang, J, additional, Reuben, A, additional, Duose, DY, additional, Fujimoto, J, additional, Roy-Chowdhuri, S, additional, Solis Soto, LM, additional, Dejima, H, additional, Parra-Cuentas, ER, additional, Mino, B, additional, Abraham, R, additional, Ikeda, N, additional, Vaporcyan, A, additional, Gibbons, D, additional, Lang, FF, additional, Luthra, R, additional, Lee, JJ, additional, Moran, C, additional, Huse, JT, additional, Kadara, H, additional, and Wistuba, II, additional
- Full Text
- View/download PDF
42. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
- Author
-
Dejima, H, primary, Hu, X, additional, Chen, R, additional, Zhang, J, additional, Fujimoto, J, additional, Parra, ER, additional, Haymaker, C, additional, Hubert, SM, additional, Douse, D, additional, Solis, LM, additional, Su, D, additional, Fukuoda, J, additional, Tabata, K, additional, Pham, HHN, additional, Mcgranahan, N, additional, Zhang, B, additional, Ye, J, additional, Ying, L, additional, Little, L, additional, Gumbs, C, additional, Chow, C, additional, Estecio, MR, additional, Godoy, MCB, additional, Antonoff, MB, additional, Sepesi, B, additional, Pass, HI, additional, Behrens, C, additional, Vaporciyan, AA, additional, Heymach, JV, additional, Scheet, P, additional, Lee, JJ, additional, Wu, J, additional, Futreal, PA, additional, Reuben, A, additional, Kadara, H, additional, and Wistuba, II, additional
- Full Text
- View/download PDF
43. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.
- Author
-
Ludmir EB, Sherry AD, Fellman BM, Liu S, Bathala T, Haymaker C, Medina-Rosales MN, Reuben A, Holliday EB, Smith GL, Noticewala SS, Nicholas S, Price TR, Martin-Paulpeter RM, Perles LA, Lee SS, Lee MS, Smaglo BG, Huey RW, Willis J, Zhao D, Cohen L, Taniguchi CM, Koay EJ, Katz MHG, Wolff RA, Das P, Pant S, Koong AC, and Tang C
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Progression-Free Survival, Neoplasm Metastasis, Adult, Carcinoma, Pancreatic Ductal therapy, Carcinoma, Pancreatic Ductal secondary, Carcinoma, Pancreatic Ductal drug therapy, Carcinoma, Pancreatic Ductal mortality, Pancreatic Neoplasms pathology, Pancreatic Neoplasms drug therapy, Pancreatic Neoplasms therapy, Pancreatic Neoplasms mortality, Antineoplastic Combined Chemotherapy Protocols therapeutic use
- Abstract
Purpose: The EXTEND trial tested the hypothesis that adding comprehensive metastasis-directed therapy (MDT) to chemotherapy would improve progression-free survival (PFS) over chemotherapy alone among patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC)., Methods: EXTEND (ClinicalTrials.gov identifier: NCT03599765) is a multicenter, phase II basket trial randomly assigning patients with ≤five metastases 1:1 to MDT plus systemic therapy versus systemic therapy. Disease progression was defined by radiologic criteria (RECIST v1.1), clinical progression, or death. The primary end point was PFS in the per-protocol population, evaluated after all patients achieved at least 6 months of follow-up. Exploratory end points included systemic immune response measures., Results: Between March 19, 2019, and February 13, 2023, 41 patients were randomly assigned and 40 were eligible for the primary analysis of PFS (19 patients in the MDT arm; 21 patients in the control arm). At a median follow-up time of 17 months, the median PFS time was 10.3 months (95% CI, 4.6 to 14.0) in the MDT arm versus 2.5 months (95% CI, 1.7 to 5.1) in the control arm. PFS was significantly improved by the addition of MDT to systemic therapy ( P = .030 for stratified log-rank test) with a hazard ratio of 0.43 (95% CI, 0.20 to 0.94). No grade ≥3 or greater adverse events related to MDT were observed. Systemic immune activation events were associated with MDT and correlated with improved PFS., Conclusion: This study supports the addition of MDT to systemic therapy for patients with oligometastatic PDAC. Induction of systemic immunity is a possible mechanism of benefit. These results warrant confirmatory trials to refine treatment strategy and provide external validation.
- Published
- 2024
- Full Text
- View/download PDF
44. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): a Multicenter, Randomized Phase II Trial.
- Author
-
Reddy JP, Sherry AD, Fellman B, Liu S, Bathala T, Haymaker C, Cohen L, Smith BD, Ramirez D, Shaitelman SF, Chun SG, Medina-Rosales M, Teshome M, Brewster A, Barcenas CH, Reuben A, Ghia AJ, Ludmir EB, Weed D, Shah SJ, Mitchell MP, Woodward WA, Gomez DR, and Tang C
- Abstract
Purpose: Prior evidence suggests a progression-free survival (PFS) benefit from adding metastasis-directed therapy (MDT) to standard-of-care (SOC) systemic therapy for patients with some oligometastatic solid tumors. Randomized trials testing this hypothesis in breast cancer have yet to be published. We sought to determine whether adding MDT to SOC systemic therapy improves PFS in oligometastatic breast cancer., Methods: EXTEND is a multicenter phase II randomized basket trial testing the addition of MDT to SOC systemic therapy in patients with ≤5 metastases (NCT03599765). Patients were randomized 1:1 to MDT (definitive local treatment to all sites of disease, plus SOC systemic therapy) or to SOC systemic therapy only. Primary endpoint was PFS, and secondary endpoints included overall survival (OS), time to subsequent line of systemic therapy, and time to the appearance of new metastases. Exploratory analyses included quality of life (QOL) and systemic immune response measures., Results: From September 2018 through July 2022, 22 and 21 patients were randomized to the MDT and no-MDT arms, respectively. At a median follow-up of 24.8 months, PFS was not improved with the addition of MDT to SOC systemic therapy (median PFS 15.6 months MDT vs 24.9 months no-MDT [hazard ratio {HR} 0.91; 95% CI 0.34-2.48, p=0.86]). Similarly, MDT did not improve OS, time to subsequent line of systemic therapy, or time to the appearance of new metastases (all p>0.05). No significant differences were found in QOL measures, systemic T-cell activation, or T-cell stimulatory cytokine concentration., Conclusion: Among patients with oligometastatic breast cancer, the addition of MDT to SOC systemic therapy did not improve PFS. These findings suggest that MDT may have no systemic benefit in otherwise unselected oligometastatic breast cancer patients, although this trial was limited by a heterogenous and small sample size and overperformance of both treatment arms., Competing Interests: Declaration of competing interest Mr Fellman reported receiving grants from the National Institutes of Health (NIH) to The University of Texas MD Anderson Cancer Center during the conduct of the study. Dr Haymaker reported receiving grants from Avenge Bio, Sanofi, Dragonfly, BTG, Iovance Biotherapeutics, and TriSalus Life Sciences; receiving personal fees from Nanobiotix; receiving speaker honoraria from the Southwest Oncology Group and the Society for Immunotherapy of Cancer; and receiving stock options from BriaCell as a member of the scientific advisory board outside the submitted work. Dr Smith reported receiving salary support from Varian Medical Systems for a strategic alliance between MD Anderson Cancer Center and Varian Medical Systems outside the submitted work and royalty and equity interest in Oncora Medical. Dr Shaitelman reported funding from the Emerson Collective Foundation and contracted research agreements with Alpha Tau, Exact Sciences, TAE Life Sciences, and Artios Pharmaceuticals, outside the submitted work. Dr. Chun declares in the past 36 months support from grants or contracts from NIH R50 CA275822 and MD Anderson; consulting fees from Curio Science, Norton Healthcare, and AstraZeneca; honoraria from Binaytara Foundation, Curio Science, Henry Ford Health Systems, Japanese Society for Radiation Oncology and Hong Kong Precision Oncology society; and support for attending meetings and/or travel from ViewRay, American Board of Radiology, Binaytara Foundation, Japanese Society for Radiation Oncology, and AstraZeneca outside the submitted work. Dr Reuben reported receiving consulting fees and honoraria from Adaptive Biotechnologies outside the submitted work. Dr Ghia reported receiving consulting fees and honoraria from Brainlab outside the submitted work. Dr. Woodward reported personal fees from Exact Sciences and Epic Sciences, outside the submitted work. Dr Gomez reported receiving grants from AstraZeneca, Merck, Varian, and Bristol Myers Squibb and receiving consulting fees and honoraria from Grail, AstraZeneca, Olympus, Johnson & Johnson, Varian, Medtronic, and Med Learning Group outside the submitted work. Dr Tang reported receiving grants from the Cancer Prevention & Research Institute of Texas (CPRIT) and the Andrew Sabin Family Foundation and being an Andrew Sabin Scholar during the conduct of the study and receiving royalties from Wolters Kluwer and consulting fees and honoraria from Bayer, Diffusion Pharmaceuticals, and The Osler Institute Lecture Series outside the submitted work. No other disclosures were reported., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
45. Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles.
- Author
-
He S, Gubin MM, Rafei H, Basar R, Dede M, Jiang X, Liang Q, Tan Y, Kim K, Gillison ML, Rezvani K, Peng W, Haymaker C, Hernandez S, Solis LM, Mohanty V, and Chen K
- Abstract
Recent developments in immunotherapy, including immune checkpoint blockade (ICB) and adoptive cell therapy (ACT), have encountered challenges such as immune-related adverse events and resistance, especially in solid tumors. To advance the field, a deeper understanding of the molecular mechanisms behind treatment responses and resistance is essential. However, the lack of functionally characterized immune-related gene sets has limited data-driven immunological research. To address this gap, we adopted non-negative matrix factorization on 83 human bulk RNA sequencing (RNA-seq) datasets and constructed 28 immune-specific gene sets. After rigorous immunologist-led manual annotations and orthogonal validations across immunological contexts and functional omics data, we demonstrated that these gene sets can be applied to refine pan-cancer immune subtypes, improve ICB response prediction and functionally annotate spatial transcriptomic data. These functional gene sets, informing diverse immune states, will advance our understanding of immunology and cancer research., Competing Interests: H.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical; K.R. and The University of Texas MD Anderson Cancer Center have an institutional financial conflict of interest with Takeda Pharmaceutical and Affimed GmbH. K.R. participates on the Scientific Advisory Board for GemoAb, AvengeBio, Virogin Biotech, GSK, Bayer, Navan Technologies, Caribou Biosciences, BitBio Limited and Innate Pharma. K.R. is the scientific founder of Syena.
- Published
- 2024
- Full Text
- View/download PDF
46. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion.
- Author
-
Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, and Zhang J
- Abstract
Studying lung adenocarcinoma (LUAD) early carcinogenesis is challenging, primarily due to the lack of LUAD precursors specimens. We amassed multi-omics data from 213 LUAD and LUAD precursors to identify molecular features underlying LUAD precancer evolution. We observed progressively increasing mutations, chromosomal aberrations, whole genome doubling and genomic instability from precancer to invasive LUAD, indicating aggravating chromosomal instability (CIN). Telomere shortening, a crucial genomic alteration linked to CIN, emerged at precancer stage. Moreover, later-stage lesions demonstrated increasing cancer stemness and decreasing alveolar identity, suggesting epithelial de-differentiation during early LUAD carcinogenesis. The innate immune cells progressively diminished from precancer to invasive LUAD, concomitant with a gradual recruitment of adaptive immune cells (except CD8
+ and gamma-delta T cells that decreased in later stages) and upregulation of numerous immune checkpoints, suggesting LUAD precancer evolution is associated with a shift from innate to adaptive immune response and immune evasion mediated by various mechanisms., Competing Interests: J.J.Z. reports research funding from Merck, Johnson and Johnson, Novartis, Summit, Hengenix and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, Innovent, Varian, Catalyst outside the submitted work. I.I.W reports Honoraria from Genentech/Roche, Bayer, Bristol-Myers Squibb, Astra Zeneca/Medimmune, Pfizer, HTG Molecular, Asuragen, Merck, GlaxoSmithKline, Guardant Health, Oncocyte, Flame, and MSD; Research support from Genentech, Oncoplex, HTG Molecular, DepArray, Merck, Bristol-Myers Squibb, Medimmune, Adaptive, Adapt immune, EMD Serono, Pfizer, Takeda, Amgen, Karus, Johnson & Johnson, Bayer, Iovance, 4D, Novartis, and Akoya. J.V.H. reports honorariums from AstraZeneca, Boehringer-Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche and Leads Biolabs. D.E.G. reports research funding from Astra-Zeneca, BerGenBio, Karyopharm, and Novocure; stock ownership in Gilead; consultant/advisory fees from Abbvie, Astra-Zeneca, Catalyst Pharmaceuticals, Daiichi-Sankyo, Elevation Oncology, Janssen Scientific Affairs, LLC, Jazz Pharmaceuticals, Regeneron Pharmaceuticals, and Sanofi; and serving as co-founder and chief scientific officer of OncoSeer Diagnostics, Inc. S.H. reports consulting fees from Guardant Health and AstraZeneca. S.M.D serves on the Scientific Advisory Boards for Early Diagnostics Inc. and LungLife AI, Inc. and has received research funding from Johnson & Johnson Lung Cancer Initiative and Novartis. The other authors declare no competing interests.- Published
- 2024
- Full Text
- View/download PDF
47. Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial.
- Author
-
Campbell MT, Balderrama-Brondani V, Jimenez C, Tamsen G, Marcal LP, Varghese J, Shah AY, Long JP, Zhang M, Ochieng J, Haymaker C, and Habra MA
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Aged, Prospective Studies, Progression-Free Survival, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors pharmacokinetics, Anilides therapeutic use, Anilides administration & dosage, Anilides adverse effects, Anilides pharmacokinetics, Pyridines therapeutic use, Pyridines administration & dosage, Pyridines adverse effects, Adrenocortical Carcinoma drug therapy, Adrenocortical Carcinoma pathology, Adrenocortical Carcinoma mortality, Adrenal Cortex Neoplasms drug therapy, Adrenal Cortex Neoplasms pathology, Adrenal Cortex Neoplasms mortality
- Abstract
Background: Adrenocortical carcinoma is a rare malignancy with poor response to systemic chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma. Cabozantinib is a multikinase inhibitor approved in multiple malignancies. This is the first prospective trial to explore the anti-tumour activity, safety, and pharmacokinetic profile of cabozantinib in patients with advanced adrenocortical carcinoma., Methods: This investigator-initiated, single-arm, phase 2 trial in adult patients (aged ≥18 years) with advanced adrenocortical carcinoma was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Eligible patients had histologically confirmed adrenocortical carcinoma, were not candidates for surgery with curative intent, had measurable disease, had an estimated life expectancy of at least 3 months, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 with adequate organ function. Patients who had used mitotane within 6 months of study participation were required to have a serum mitotane level of less than 2 mg/L. Patients were given oral cabozantinib 60 mg daily with the option of dose reduction to manage adverse events. The primary endpoint was progression-free survival at 4 months, assessed in all patients who received at least one dose of study drug per protocol. This study is registered with ClinicalTrials.gov, NCT03370718, and is now complete., Findings: Between March 1, 2018, and May 31, 2021, we enrolled 18 patients (ten males and eight females), all of whom received at least one dose of study treatment. Of the 18 patients, eight (44%) had an ECOG performance status of 0, nine (50%) patients had a performance status of 1, and one (6%) patient had a performance status of 2. Median follow-up was 36·8 months (IQR 30·2-50·3). At 4 months, 13 (72·2%; 95% CI 46·5-90·3) of 18 patients had progression-free survival and median progression-free survival was 6 months (95% CI 4·3 to not reached). One patient remains on treatment. Treatment-related adverse events of grade 3 or worse occurred in 11 (61%) of 18 patients. The most common grade 3 adverse events were lipase elevation (three [17%] of 18 patients), elevated γ-glutamyl transferase concentrations (two [11%] patients), elevated alanine aminotransferase concentrations (two [11%] patients), hypophosphatemia (two [11%] patients), and hypertension (two [11%] patients). One (6%) of 18 patients had grade 4 hypertension. No treatment related deaths occurred on study., Interpretation: Cabozantinib in advanced adrenocortical carcinoma showed promising efficacy with a manageable and anticipated safety profile. Further prospective studies with cabozantinib alone and in combination with immune checkpoint therapy are ongoing., Funding: Exelixis., Competing Interests: Declaration of interests MTC reports institutional research funding from ApricityHealth, AstraZeneca, Exelixis, Janssen, Pfizer, SeaGen, and the United States Department of Defense; speaker's Bureau participation with Curio Science, Dava Oncology, and MJH Life Sciences; and advisory board fees or honorarium from Exelixis, Eisai, and SeaGen. CJ reports research grants paid to their institution from Exelixis, Merck Sharp & Dohme, Progenics pharmaceuticals, and Lantheus pharmaceuticals; and participation of scientific advisory boards for Merck Sharp & Dohme and Lantheus pharmaceuticals. CH reports research grants to their institution from Avenge Bio, Dragonfly Therapeutics, BTG, Sanofi, and Iovance; stock options from BriaCell as a scientific advisory board member; and travel expenses or honoraria from the Hope Foundation and the Society for Immunotherapy of Cancer, outside the scope of the submitted work. MAH reports research grants to their institution from Exelixis, Merck, and Corcept; and honoraria from HRA pharma. All other authors declare no competing interests., (© 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
48. Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.
- Author
-
Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, and Haymaker C
- Subjects
- Humans, Nivolumab, Multiomics, Antineoplastic Combined Chemotherapy Protocols adverse effects, Immunotherapy, Lung pathology, Epithelial Cells pathology, Ipilimumab therapeutic use, Tumor Microenvironment, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell genetics
- Abstract
Purpose: Identifying molecular and immune features to guide immune checkpoint inhibitor (ICI)-based regimens remains an unmet clinical need., Experimental Design: Tissue and longitudinal blood specimens from phase III trial S1400I in patients with metastatic squamous non-small cell carcinoma (SqNSCLC) treated with nivolumab monotherapy (nivo) or nivolumab plus ipilimumab (nivo+ipi) were subjected to multi-omics analyses including multiplex immunofluorescence (mIF), nCounter PanCancer Immune Profiling Panel, whole-exome sequencing, and Olink., Results: Higher immune scores from immune gene expression profiling or immune cell infiltration by mIF were associated with response to ICIs and improved survival, except regulatory T cells, which were associated with worse overall survival (OS) for patients receiving nivo+ipi. Immune cell density and closer proximity of CD8+GZB+ T cells to malignant cells were associated with superior progression-free survival and OS. The cold immune landscape of NSCLC was associated with a higher level of chromosomal copy-number variation (CNV) burden. Patients with LRP1B-mutant tumors had a shorter survival than patients with LRP1B-wild-type tumors. Olink assays revealed soluble proteins such as LAMP3 increased in responders while IL6 and CXCL13 increased in nonresponders. Upregulation of serum CXCL13, MMP12, CSF-1, and IL8 were associated with worse survival before radiologic progression., Conclusions: The frequency, distribution, and clustering of immune cells relative to malignant ones can impact ICI efficacy in patients with SqNSCLC. High CNV burden may contribute to the cold immune microenvironment. Soluble inflammation/immune-related proteins in the blood have the potential to monitor therapeutic benefit from ICI treatment in patients with SqNSCLC., (©2024 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
49. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes.
- Author
-
Seth S, Chen R, Liu Y, Fujimoto J, Hong L, Reuben A, Varghese S, Behrens C, McDowell T, Soto LS, Haymaker C, Weissferdt A, Kalhor N, Wu J, Le X, Vokes NI, Cheng C, Heymach JV, Gibbons DL, Futreal PA, Wistuba II, Kadara H, Zhang J, Moran C, and Zhang J
- Abstract
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of non-small cell lung cancer (NSCLC), characterized by the presence of epithelial and sarcoma-like components. The molecular and immune landscape of PSC has not been well defined., Methods: Multiomics profiling of 21 pairs of PSCs with matched normal lung tissues was performed through targeted high-depth DNA panel, whole-exome, and RNA sequencing. We describe molecular and immune features that define subgroups of PSC with disparate genomic and immunogenic features as well as distinct clinical outcomes., Results: In total, 27 canonical cancer gene mutations were identified, with TP53 the most frequently mutated gene, followed by KRAS . Interestingly, most TP53 and KRAS mutations were earlier genomic events mapped to the trunks of the tumors, suggesting branching evolution in most PSC tumors. We identified two distinct molecular subtypes of PSC, driven primarily by immune infiltration and signaling. The Immune High (IM-H) subtype was associated with superior survival, highlighting the impact of immune infiltration on the biological and clinical features of localized PSCs., Conclusions: We provided detailed insight into the mutational landscape of PSC and identified two molecular subtypes associated with prognosis. IM-H tumors were associated with favorable recurrence-free survival and overall survival, highlighting the importance of tumor immune infiltration in the biological and clinical features of PSCs., Competing Interests: Ignacio I. Wistuba reports consulting or advisory roles for AstraZeneca/MedImmune, Bayer, Bristol‐Myers Squibb, Genentech/Roche, GlaxoSmithKline, Guardant Health, HTG Molecular Diagnostics, Merck, MSD Oncology, OncoCyte, Jansen, Novartis, Flame Inc, and Pfizer; has received grants and personal fees from Genentech/Roche, Bristol Myers Squibb, AstraZeneca/MedImmune, HTG Molecular, Merck, and Guardant Health; has received personal fees from GlaxoSmithKline and Oncocyte, Daiichi‐Sankyo, Roche, Astra Zeneca, Pfizer, and Bayer; has received research funding to his institution from 4D Molecular Therapeutics, Adaptimmune, Adaptive Biotechnologies, Akoya Biosciences, Amgen, Bayer, EMD Serono, Genentech, Guardant Health, HTG Molecular Diagnostics, Iovance Biotherapeutics, Johnson & Johnson, Karus Therapeutics, MedImmune, Merck, Novartis, OncoPlex Diagnostics, Pfizer, Takeda, and Novartis. Jianjun Zhang reports research funding from Merck, Johnson and Johnson, and consultant fees from BMS, Johnson and Johnson, AstraZeneca, Geneplus, OrigMed, and Innovent outside the submitted work. John V. Heymach reports honorariums from AstraZeneca, Boehringer‐Ingelheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, EMD Serono, Sanofi, Takeda, Mirati Therapeutics, BMS, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Roche and Leads Biolabs. Runzhe Chen reports stock options from BeiGene outside the submitted work. Cara Haymaker received funding to institution from Avenge Bio, Sanofi, Dragonfly, BTG, Iovance Biotherapeutics, KSQ, Obsidian and Virogen, personal fees from Regeneron and stock options from BriaCell as a member of the scientific advisory board outside the submitted work. Alexandre Reuben serves on the Scientific Advisory Board and has received honoraria from Adaptive Biotechnologies. Natalie I Vokes reports consulting roles for Sanofi, Oncocyte, Lilly, Regeneron, Amgen, Xencor, Astra Zeneca, Tempus and Pfizer, and travel reimbursement from regeneron. Professor Jianjun Zhang is a member of the Cancer Innovation Editorial Board. To minimize bias, he was excluded from all editorial decision‐making related to the acceptance of this article for publication. The remaining authors declare no conflict of interest., (© 2024 The Authors. Cancer Innovation published by John Wiley & Sons Ltd on behalf of Tsinghua University Press.)
- Published
- 2024
- Full Text
- View/download PDF
50. Interpretable Spatial Gradient Analysis for Spatial Transcriptomics Data.
- Author
-
Liang Q, Soto LS, Haymaker C, and Chen K
- Abstract
Cellular anatomy and signaling vary across niches, which can induce gradated gene expressions in subpopulations of cells. Such spatial transcriptomic gradient (STG) makes a significant source of intratumor heterogeneity and can influence tumor invasion, progression, and response to treatment. Here we report Local Spatial Gradient Inference (LSGI), a computational framework that systematically identifies spatial locations with prominent, interpretable STGs from spatial transcriptomic (ST) data. To achieve so, LSGI scrutinizes each sliding window employing non-negative matrix factorization (NMF) combined with linear regression. With LSGI, we demonstrated the identification of spatially proximal yet opposite directed pathway gradients in a glioblastoma dataset. We further applied LSGI to 87 tumor ST datasets reported from nine published studies and identified both pan-cancer and tumor-type specific pathways with gradated expression patterns, such as epithelial mesenchymal transition, MHC complex, and hypoxia. The local gradients were further categorized according to their association to tumor-TME (tumor microenvironment) interface, highlighting the pathways related to spatial transcriptional intratumoral heterogeneity. We conclude that LSGI enables highly interpretable STG analysis which can reveal novel insights in tumor biology from the increasingly reported tumor ST datasets., Competing Interests: Competing Interests The authors declare no competing interests.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.